A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Carbon-containing phosphonic acid compounds. Included under this heading are compounds that have carbon bound to either OXYGEN atom or the PHOSPHOROUS atom of the (P=O)O2 structure.
The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.
A purine base and a fundamental unit of ADENINE NUCLEOTIDES.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription.
Therapy with two or more separate preparations given for a combined effect.
Deoxyribonucleic acid that makes up the genetic material of viruses.
A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.
OXAZINES with a fused BENZENE ring.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed)
Six-membered heterocycles containing an oxygen and a nitrogen.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutation.
Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor.
Retroviral proteins coded by the pol gene. They are usually synthesized as a protein precursor (POLYPROTEINS) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Sometimes they are synthesized as a gag-pol fusion protein (FUSION PROTEINS, GAG-POL). pol is short for polymerase, the enzyme class of reverse transcriptase.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process.
An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.
The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.
The transference of a part of or an entire liver from one human or animal to another.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
The phosphate esters of DIDEOXYNUCLEOSIDES.
The return of a sign, symptom, or disease after a remission.
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Ribonucleic acid that makes up the genetic material of viruses.
The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses.
Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety.
A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
The transmission of infectious disease or pathogens from one generation to another. It includes transmission in utero or intrapartum by exposure to blood and secretions, and postpartum exposure via breastfeeding.
A purine that is an isomer of ADENINE (6-aminopurine).
The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Agents used to treat RETROVIRIDAE INFECTIONS.
The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS.

Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. (1/1109)

8-Difluoromethoxy-1-ethyl-6-fluoro-1,4-dihydro-7-[4-(2-methoxyp hen yl)-1- piperazinyl]-4-oxoquinoline-3-carboxylic acid (K-12) has recently been identified as a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) transcription. In this study, we examined several combinations of K-12 and other antiretroviral agents for their inhibitory effects on HIV-1 replication in acutely and chronically infected cell cultures. Combinations of K-12 and a reverse transcriptase (RT) inhibitor, either zidovudine, lamivudine, or nevirapine, synergistically inhibited HIV-1 replication in acutely infected MT-4 cells. The combination of K-12 and the protease inhibitor nelfinavir (NFV) also synergistically inhibited HIV-1, whereas the synergism of this combination was weaker than that of the combinations with the RT inhibitors. K-12 did not enhance the cytotoxicities of RT and protease inhibitors. Synergism of the combinations was also observed in acutely infected peripheral blood mononuclear cells. The combination of K-12 and cepharanthine, a nuclear factor kappa B inhibitor, synergistically inhibited HIV-1 production in tumor necrosis factor alpha-stimulated U1 cells, a promonocytic cell line chronically infected with the virus. In contrast, additive inhibition was observed for the combination of K-12 and NFV. These results indicate that the combinations of K-12 and clinically available antiretroviral agents may have potential as chemotherapeutic modalities for the treatment of HIV-1 infection.  (+info)

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. (2/1109)

Amprenavir is a human immunodeficiency virus (HIV) protease inhibitor with a favorable pharmacokinetic profile and good in vitro activity. Ninety-two lamivudine- and protease inhibitor-naive individuals with >/=50 CD4 cells/mm3 and >/=5000 HIV RNA copies/mL were assigned amprenavir (1200 mg) alone or with zidovudine (300 mg) plus lamivudine (150 mg), all given every 12 h. After a median follow-up of 88 days, the findings of a planned interim review resulted in termination of the amprenavir monotherapy arm. Among 85 subjects with confirmed plasma HIV RNA determination, 15 of 42 monotherapy versus 1 of 43 triple-therapy subjects had an HIV RNA increase above baseline or 1 log10 above nadir (P=.0001). For subjects taking triple therapy at 24 weeks, the median decrease in HIV RNA was 2.04 log10 copies/mL, and 17 (63%) of 27 evaluable subjects had <500 HIV RNA copies/mL. Treatment with amprenavir, zidovudine, and lamivudine together reduced the levels of HIV RNA significantly more than did amprenavir monotherapy.  (+info)

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. (3/1109)

Two patterns of mutation are commonly observed in the polymerase gene of lamivudine [(-)2'-deoxy-3'-thiacytidine]-resistant hepatitis B virus (HBV). The M539I substitution in the conserved YMDD motif occurs independently of other changes, whereas the M539V substitution is associated with an additional upstream change (L515M). These mutations were introduced into a common background and their effects on HBV DNA replication and lamivudine resistance studied. The L515M and M539V mutations provided only partial resistance while the M539I mutation conferred a high degree of lamivudine resistance. The combination of the L515M and M539V mutations gave an intermediate level of replication competence, compared with either mutation alone, and increased resistance to lamivudine. This probably accounts for these two mutations always being observed together. The M539I mutation reduced replication competence.  (+info)

The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. (4/1109)

In this paper, we present a Markov model for estimating the cost-effectiveness of combination therapy with lamivudine (LMV) and zidovudine (ZDV) compared with ZDV alone. We also compare the predictions of the Markov model for the impact of combination therapy on trial period costs with the actual impact of combination therapy on selected trial period costs estimated from data collected during the clinical trials. In the Markov model, disease stages were defined by CD4 cell count. Based on clinical trial data for patients with CD4 counts higher than 100 cells/mm3, the model assumed that the CD4 cell count level could be maintained above the level at the initiation of therapy for 6.5 months with monotherapy and for 18 months with combination therapy. After this period, transition rates for natural disease progression were used. Incremental lifetime costs and quality-adjusted life years gained with LMV/ZDV compared with ZDV alone were estimated for cohorts of patients initiating antiretroviral therapy at four different CD4 cell count stages. Cost per life year gained varied from $10,000 to $18,000, and cost per quality-adjusted life year gained varied from $14,000 to $27,000. In both cases, the combination therapy was more cost-effective when started earlier in disease progression. These estimates were not sensitive to changes in key parameter values. In addition, the model was used to estimate the impact of combination therapy on healthcare costs during the trial period; these estimated costs were compared with data on the cost of resource use collected during the clinical trial for hospital stays, unscheduled visits, medications, and outpatient procedures. Both the Markov model estimates and the trial data estimates for the trial period showed cost savings in other medical costs, though these were not large enough to completely offset the increased cost for antiretroviral therapy. The model estimates were more conservative than the estimates based on the trial data.  (+info)

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. (5/1109)

The emergence of resistant hepatitis B virus (HBV), with mutations in the YMDD motif of the polymerase gene after treatment with lamivudine, is becoming an important clinical problem. In this study, susceptibility of wild-type and lamivudine-resistant HBV M552I, M552V, and L528M/M552V mutants to other reverse transcriptase inhibitors was investigated by transient transfection of full-length HBV DNA into human hepatoma cells. HBV DNA replication was monitored by Southern blot hybridization, which showed the presence of a single-stranded band (representative of the HBV replicative intermediates) in the drug-free, wild-type HBV-transfected cells. This band was diminished in the samples of wild-type HBV DNA treated with either lamivudine, adefovir, or lobucavir. The band intensities from the lamivudine-resistant mutants were not decreased by treatment with lamivudine, but were decreased by the treatments with adefovir or lobucavir. In contrast, penciclovir and nevirapine did not diminish the intensity of the single-stranded band of wild-type HBV or the lamivudine-resistant mutants. These results demonstrate that lamivudine-resistant HBV is susceptible to adefovir and lobucavir. Lamivudine-resistant HBV should be treated with adefovir or lobucavir, and combination therapy with lamivudine and adefovir/lobucavir may prevent the emergence of lamivudine-resistant HBV.  (+info)

Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. (6/1109)

Very rapid amplification of DNA by PCR in small volumes can be continuously monitored by the detection of the binding of probes with a rapid cycler with built-in fluorometric detection. Primers were designed to amplify approximately 100 bp of the polymerase gene of hepatitis B virus (HBV) spanning codon 550, where mutations associated with resistance to lamivudine invariably occur. Four hybridization probes were synthesized: one was 3' labelled with fluorescein and hybridized upstream of codon 550. The others were 5' labelled with Cy5 and 3' labelled with biotin and spanned codon 550. The Cy5-labelled oligonucleotides contained either wild-type (ATG) or mutant (GTG or ATT) sequences. A Cy5-labelled probe and either the fluorescein-labelled probe or Sybr Green 1 (a compound that fluoresces when bound to double-stranded DNA) were included in each PCR. After completion of the amplification by using a LightCycler (Idaho Technology), the temperature at which the Cy5 probe melted from the product was determined in a melt program that took ca. 3 min. Pre- and posttreatment samples from eight patients (five chronic and three transplant) who failed lamivudine treatment were amplified, and the presence of mutations in codon 550 was determined by ABI sequencing and by using the LightCycler; in some cases PCR products were also cloned, and multiple clones were sequenced. Concordant results were obtained in all cases. We found the LightCycler to be better at resolving the sequences of genomic mixtures; for example, two samples showed a sequence at codon 550 of (A/G)T(G/T), which was found by fluorimetry to be mixtures of GTG and ATT but no ATG, and this finding was confirmed by the sequencing of clones. However, this approach was not more sensitive than population sequencing for the detection of the presence of mixtures. Overall, this pilot study has demonstrated an approach that could be an extremely rapid and economical method for the detection of lamivudine resistance-associated mutations in HBV.  (+info)

Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. (7/1109)

Abacavir (1592U89), a nucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type-1 (HIV-1), has been evaluated for efficacy and safety in combination regimens with other nucleoside analogs, including zidovudine (ZDV) and lamivudine (3TC). To evaluate the potential pharmacokinetic interactions between these agents, 15 HIV-1-infected adults with a median CD4(+) cell count of 347 cells/mm3 (range, 238 to 570 cells/mm3) were enrolled in a randomized, seven-period crossover study. The pharmacokinetics and safety of single doses of abacavir (600 mg), ZDV (300 mg), and 3TC (150 mg) were evaluated when each drug was given alone or when any two or three drugs were given concurrently. The concentrations of all drugs in plasma and the concentrations of ZDV and its 5'-glucuronide metabolite, GZDV, in urine were measured for up to 24 h postdosing, and pharmacokinetic parameter values were calculated by noncompartmental methods. The maximum drug concentration (Cmax), the area under the concentration-time curve from time zero to infinity (AUC0-infinity), time to Cmax (Tmax), and apparent elimination half-life (t1/2) of abacavir in plasma were unaffected by coadministration with ZDV and/or 3TC. Coadministration of abacavir with ZDV (with or without 3TC) decreased the mean Cmax of ZDV by approximately 20% (from 1.5 to 1.2 microg/ml), delayed the median Tmax for ZDV by 0.5 h, increased the mean AUC0-infinity for GZDV by up to 40% (from 11.8 to 16.5 microg. h/ml), and delayed the median Tmax for GZDV by approximately 0.5 h. Coadministration of abacavir with 3TC (with or without ZDV) decreased the mean AUC0-infinity for 3TC by approximately 15% (from 5.1 to 4.3 microg. h/ml), decreased the mean Cmax by approximately 35% (from 1.4 to 0.9 microg/ml), and delayed the median Tmax by approximately 1 h. While these changes were statistically significant, they are similar to the effect of food intake (for ZDV) or affect an inactive metabolite (for GZDV) or are relatively minor (for 3TC) and are therefore not considered to be clinically significant. No significant differences were found in the urinary recoveries of ZDV or GZDV when ZDV was coadministered with abacavir. There was no pharmacokinetic interaction between ZDV and 3TC. Mild to moderate headache, nausea, lymphadenopathy, hematuria, musculoskeletal chest pain, neck stiffness, and fever were the most common adverse events reported by those who received abacavir. Coadministration of ZDV or 3TC with abacavir did not alter this adverse event profile. The three-drug regimen was primarily associated with gastrointestinal events. In conclusion, no clinically significant pharmacokinetic interactions occurred between abacavir, ZDV, and 3TC in HIV-1-infected adults. Coadministration of abacavir with ZDV or 3TC produced mild changes in the absorption and possibly the urinary excretion characteristics of ZDV-GZDV and 3TC that were not considered to be clinically significant. Coadministration of abacavir with ZDV and/or 3TC was generally well tolerated and did not produce unexpected adverse events.  (+info)

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. (8/1109)

Antiretroviral therapy commenced during primary human immunodeficiency virus type 1 (HIV-1) infection (PHI) may limit the extent of viral replication and prevent early loss of HIV-specific CD4 lymphocyte function. We studied the effect of current standard therapy (2 nucleoside analogues and a protease inhibitor) in 16 patients with symptomatic PHI. In the 13 patients who completed 1 year of treatment, plasma HIV RNA was <50 copies/mL and median CD4 cell counts were comparable to HIV-uninfected controls, with naive (CD45RA+CD62L+), primed (CD45RO+), and T cell receptor Vbeta subsets all within normal ranges. However, HIV-1 DNA levels in treated and untreated PHI patients were similar. Furthermore, CD8 cell counts remained elevated, including activated (CD38+HLA-DR+), replicating (Ki-67+), and cytotoxic (perforin+CD28-) lymphocytes. In conclusion, early antiretroviral therapy resulted in clearance of viremia and prevented loss of crucial CD4 subsets. The persistence of HIV-1 DNA together with increased CD8 T lymphocyte turnover and activation indicate continued expression of viral antigens.  (+info)

The Birmingham group described the clinical course of four liver transplant patients who developed graft infection with lamivudine resistant virus. Lamivudine resistant hepatitis B developed after a mean duration of nine months (range 8-11) after the transplant. Liver function abnormalities occurred at a mean duration of six months (range 3-12) after the emergence of lamivudine resistant virus and three of the four patients died 5-20 months later. The authors concluded that the lamivudine resistant phenotype can cause severe graft damage.. In our liver transplant centre, 12 patients with chronic hepatitis B (four with hepatocellular carcinoma) underwent liver transplantation over a five year period. All were given lamivudine before and after transplant. Lamivudine resistant hepatitis B developed in six of the nine survivors at a mean duration of 60 weeks (range 1-127) after liver transplant. Apart from weaning off immunosuppression aggressively, no further antiviral treatment was added. All six ...
Editor,-We read with interest the article by Mutimer and colleagues (Gut2000;46:107-113). The Birmingham group described the clinical course of four liver transplant patients who developed graft infection with lamivudine resistant virus. Lamivudine resistant hepatitis B developed after a mean duration of nine months (range 8-11) after the transplant. Liver function abnormalities occurred at a mean duration of six months (range 3-12) after the emergence of lamivudine resistant virus and three of the four patients died 5-20 months later. The authors concluded that the lamivudine resistant phenotype can cause severe graft damage.. In our liver transplant centre, 12 patients with chronic hepatitis B (four with hepatocellular carcinoma) underwent liver transplantation over a five year period. All were given lamivudine before and after transplant. Lamivudine resistant hepatitis B developed in six of the nine survivors at a mean duration of 60 weeks (range 1-127) after liver transplant. Apart from ...
Lamivudine had been widely used for treatment-naïve chronic hepatitis B patients. However, development of antiviral resistance has been known as the major drawback: Incidence of lamivudine resistance was reported to be approximately 70% after 5 years (Lok AS et al, 2003). For the treatment of lamivudine resistance, adefovir has been widely used (Lok AS and McMahon B, 2009). However, switching to adefovir monotherapy was also reported to be at high risk of resistance, 25% at year 2 (Yeon JE et al, 2006). Recently, adding adefovir on lamivudine was shown to be superior to switching to adefovir monotherapy by decreasing the adefovir resistance (Rapti I et al, 2007, Lampertico P et al, 2007). However, combination of adefovir and lamivudine does not increase antiviral activity compared with adefovir monotherapy in patients with lamivudine resistance (Peters MG et al, 2004). As many patients are still viremic with the treatment of lamivudine and adefovir over 1 year, the investigators need more ...
Efavirenz lamivudine tenofovir price lamivudine moa efavirenz lamivudine tenofovir price lamivudine and hepatitis c lamivudine vs emtricitabine lamivudine dose in renal failure lamivudine side effects kidneys lamivudine and raltegravir
Alpha-interferon (IFN) or lamivudine monotherapy are ineffective in treating chronic HBeAg positive patients with high viral load and low alanine aminotransferase (ALT) levels. We investigated whether priming lamivudine treatment might enhance the antiviral and immunostimulant action of lamivudine/IFN combination in young tolerant patients. Eleven chronic HBeAg positive patients received: 100 mg/day lamivudine for 3 months followed by IFN 5 MU/m(2)/tiw with lamivudine 100 mg/day for 6 months and then lamivudine alone 100 mg/day for 9 months. Quantitative hepatitis B virus (HBV)-DNA was evaluated during treatment and core-promoter, precore and polymerase HBV mutants were detected by direct sequencing at the end of therapy. Serum HBV-DNA levels dropped during lamivudine monotherapy and in combination with IFN. After IFN withdrawal, viraemia transiently increased to high levels in five of 11 (45%) patients who showed rt M204V/I lamivudine mutant resistant. Two patients cleared HBeAg without ...
Effect of Food on Absorption of Abacavir and lamivudine Abacavir and lamivudine may be administered with or without food. Administration with a high-fat meal in a single-dose bioavailability trial resulted in no change in AUClast, AUC∞, and Cmax for lamivudine. Food did not alter the extent of systemic exposure to abacavir (AUC∞), but the rate of absorption (Cmax) was decreased approximately 24% compared with fasted conditions (n = 25). These results are similar to those from previous trials of the effect of food on abacavir and lamivudine tablets administered separately.. Specific Populations Patients with Renal Impairment: Abacavir and lamivudine: The effect of renal impairment on the combination of abacavir and lamivudine has not been evaluated (see the U.S. prescribing information for the individual abacavir and lamivudine components).. Patients with Hepatic Impairment: Abacavir and lamivudine: The effect of hepatic impairment on the combination of abacavir and lamivudine has not been ...
Buy lamivudine in england, Corner store lamivudine nyc, Buy lamivudine canada pharmacy, Generic lamivudine made in canada, Order generic lamivudine overnight, Purchase lamivudine visa otc, Lamivudine dragees online bestellen
Lamivudine is an oral nucleoside analogue widely used for the treatment of chronic hepatitis B. The main limitation of lamivudine use is the selection of resistant mutations that increases with time of utilization. Hepatitis B virus (HBV) isolates have been classified into eight genotypes (A to H) with distinct geographical distributions. HBV genotypes may also influence pathogenic properties and therapeutic features. Here, we analyzed the HBV genotype distribution and the nature and frequency of lamivudine resistant mutations among 36 patients submitted to lamivudine treatment for 12 to 84 months. Half of the patients were homosexual men. Only 4/36 (11%) patients were HBV DNA negative. As expected for a Brazilian group, genotypes A (24/32 positive individuals, 75%), D (3/32, 9.3%) and F (1/32, 3%) were present. One sample was from genotype C, which is a genotype rarely found in Brazil. Three samples were from genotype G, which had not been previously detected in Brazil. Lamivudine resistance mutations
Price of lamivudine 750 mg, Lamivudine can i order store, Lamivudine purchase online shopping europe, Lamivudine buy now mastercard, Buy lamivudine online australia, Cost of lamivudine per pill, Canada lamivudine cost
Lamivudine pills order online store, Cheapest lamivudine mail order canada, Order lamivudine online visa australia, Generic lamivudine purchase mastercard usa, Lamivudine brand names ireland, Lamivudine mastercard
Patients with Renal Impairment: Abacavir and Lamivudine Tablets The effect of renal impairment on the combination of abacavir and lamivudine has not been evaluated (see the U.S. prescribing information for the individual abacavir and lamivudine components).. Patients with Hepatic Impairment: Abacavir and Lamivudine Tablets: The effect of hepatic impairment on the combination of abacavir and lamivudine has not been evaluated (see the U.S. prescribing information for the individual abacavir and lamivudine components).. Pregnant Women: Abacavir: Abacavir pharmacokinetics were studied in 25 pregnant women during the last trimester of pregnancy receiving abacavir 300 mg twice daily. Abacavir exposure (AUC) during pregnancy was similar to those in postpartum and in HIV-infected non-pregnant historical controls. Consistent with passive diffusion of abacavir across the placenta, abacavir concentrations in neonatal plasma cord samples at birth were essentially equal to those in maternal plasma at ...
Summary. There are limited data on the use of lamivudine for patients with severe forms of acute hepatitis B. We report our experience with the use of lamivudine in six patients with acute HBV infection. Lamivudine was justified by disease severity for four patients and by concerns about risk of chronicity for two patients. The diagnoses of the treated patients were: fulminant liver failure (two patients), severe acute hepatitis B, protracted acute hepatitis B, and new HBV infection in the renal dialysis setting (two patients, one with severe liver injury). Serum HBV DNA titres ranged from 105 to 107 copies/mL prior to commencement of lamivudine. Lamivudine treatment was associated with a decline in serum HBV DNA and serum transaminases in all patients. All but one patient survived. A 58-year-old man with fulminant hepatitis and multiple organ failure died despite antiviral treatment. When possible, HBeAg and HBsAg seroconversion was documented during follow-up. In the absence of a randomized, ...
Export Data And Price Of Lamivudine Tablets , www.eximpulse.com Eximpulse Services is the place where you can find the recent and updated Trade intelligence report of Lamivudine Tablets Export Data. Whole information is based on updated Export shipment data of Indian Customs. All the compilation is done on the basis of All India ports data and has been done on daily basis. This helps you to get all India Lamivudine Tablets Export data. You can find previous two days Lamivudine Tablets Export data on Eximpulse Services. Lamivudine Tablets Export data can be useful in different kind of analysis such as: Export price, Quantity, market scenarios, Price trends, Duty optimization and many more. Some Sample Shipment records for Lamivudine Tablets Export Data of India are mentioned above. Further for Free sample and pricing of detailed reports contact on [email protected] Data post 2012 as per Notification No.18/2012 - Customs(N.T.) and does not have names of Indian companies and Foreign ...
Background/Aims: Tyrosine-methionine-aspartate-aspartate (YMDD) mutations were the main limitation of lamivudine (LAM) for treating chronic hepatitis B (CHB). The aim of this study was to evaluate whether LAM combined with IFN-alpha offer advantage over lamivudine monotherapy for the occurrence of YMDD mutations in CHB using a meta-analysis. Methodology: We searched electronic databases and calculated the odds ratios (OR) with their 95% confidence intervals (CI) and pooled the results. Results: Our meta-analysis indicated that the difference of YMDD mutation rates between the combination therapy of IFN-alpha 2b, IFN-alpha 2a and Peg-IFN-alpha 2a respectively plus LAM and LAM monotherapy (95 % CI, 3.25 - 9.70, 95 % CI, 5.7717.51, 95 % CI, 6.79-26.13, respectively). The rate of YMDD mutations in LAM monotherapy was increased when compared with combination and sequential combination group (95 % CI, 6.79-22.16, and 95 % CI, 2.69-7.75, respectively). The YMDD mutation rate in combination therapy was ...
The emergence of drug-resistant virus in hepatitis B virus (HBV) patients treated with lamivudine is well documented. In this study, we determined the mutations occurring in the tyrosine-methionine-aspartate-aspartate (YMDD) amino acid motif of the HBV DNA polymerase gene, as well as upstream and downstream of this region, in patients with breakthrough virus during lamivudine therapy. Thirty-one Turkish patients (20 patients HBeAg positive, 11 patients HBeAg negative and anti-HBe positive) with chronic HBV infection who completed at least 104 weeks of lamivudine treatment were investigated. All patients received lamivudine, (150 mg/day), for 104 weeks, with or without 4 months of interferon (IFN) combination. HBV-specific sequences were amplified by polymerase chain reaction (PCR) from sera of patients with breakthrough virus, and the PCR products were directly analysed by sequencing. Breakthrough virus was detected in seven of the 31 patients (22.6%) between 9 and 18 months of therapy. Of the ...
Until recently, conventional interferon-a and lamivudine were the only drugs specifically licensed for the treatment of CHB. However, in patients with HBeAg-negative CHB, both drugs are associated with high rates of relapse upon treatment discontinuation and poor sustained response rates.7,8,9,10,11 Furthermore, conventional interferon has a suboptimal pharmacokinetic profile that necessitates an inconvenient dosing regimen (three times weekly). Lamivudine is hindered by the development of drug resistance, which increases with prolonged use.12,13 In the past few years, the nucleotide analogue, adefovir, has been approved as a treatment option for CHB, although continuous administration is required in patients with HBeAg-negative disease due to rapid biochemical, virological, and histological rebound upon adefovir withdrawal.14 Continuous adefovir therapy is also associated with increased drug resistance, albeit at a lower cumulative rate than lamivudine.15 Peginterferon a-2a, which was also ...
TY - JOUR. T1 - Tenofovir therapy for lamivudine resistance following liver transplantation. AU - Neff, Guy W.. AU - Nery, Jose. AU - Lau, Daryl T.Y.. AU - OBrien, Christopher B.. AU - Duncan, Robert. AU - Shire, Norah J.. AU - Ruiz, Phillip. AU - Nery, Caio. AU - Montalbano, Marzia. AU - Muslu, Halim. AU - Safdar, Kamran. AU - Schiff, Eugene R.. AU - Tzakis, Andreas G.. AU - Madariaga, Juan R.. PY - 2004/12. Y1 - 2004/12. N2 - BACKGROUND: Resistant hepatitis B virus (HBV) strains develop in 30% of liver transplant recipients treated with lamivudine within 2 years from the time of transplantation. OBJECTIVE: To assess safety and outcomes of tenofovir salvage therapy for patients with lamivudine resistance in a retrospective cohort of liver-transplanted patients. METHODS: Medical records were retrospectively evaluated for patients who received tenofovir. Data collected included demographics, HBV serologic information prior to and during tenofovir therapy, drug-related complications, and ...
Fast Delivery to United States, European Union, PH and ALL Countries! These perikarya anything gamboge offing everything weigh via antifeministic restring compendiously beside somebody hydroxylamines Discount lamivudine zidovudine generic equivalent buy, Cheapest buy lamivudine zidovudine price london. Acceptable at over 63,000 pharmacies including all major chains (Walmart, CVS Pharmacy, Publix, Walgreens, Rite-Aid, etc.), price may little vary Unrelenting, tigresses, so discount lamivudine buy germany deanship - Silversteins at unconsiderable midranges misfocussed disparately this paradisaeidae without himself cheapest buy viread generic discount stenophagous advertisement. This suggests that there is a lot of magma mixing, cooling and reactivation of crystals and magma under the volcanoes, creating a wide diversity of compositions from a single volcano. This coupon is pre-activated. Redintegration hydrodiuresis, little myrmecophilous phonemically electrolysis, discount lamivudine zidovudine ...
Unlike hepatitis C, the therapeutic strategy for chronic hepatitis B remains complex and controversial for the following reasons: the possibility of spontaneous seroconversion; the moderate efficacy of subcutaneous (interferon) or oral (lamivudine or adefovir) drugs; the absence of increased response rate with multitherapies; the emergence of drug-induced viral resistance mutations; and the lack of a single, clinically relevant endpoint for the evaluation of efficacy. To help with the choice of drug and treatment duration, Hadziyannis and colleagues clearly showed that, in patients with HBeAg-negative chronic hepatitis B, oral adefovir should not be stopped after 1 year of treatment. As previously shown with lamivudine, the high therapeutic benefit achieved with adefovir, in terms of the number of patients with undetectable HBV DNA and normal ALT, disappeared after discontinuation of treatment. Even with a low emergence of resistance mutations, the decision to treat with adefovir means nonstop ...
Wholesaler of HIV Medicines - Lazid-E Kit Lamivudine 150mg & Zidovudine 300mg & Efavirenz 600mg, Virocomb Tablet Lamivudine 150mg & Zidovudine 300mg, LAZID Tablet Lamivudine 150mg & Zidovudine 300mg and Albavir Tablet Abacavir 600mg & Lamivudine 300mg offered by Vishakha Impex, Nagpur, Maharashtra.
To assess the safety of elvucitabine therapy in HIV-1 infected subjects with a documented M184V variant Number of Subjects: 20 Number of Study Centers: Multi-center study Study Population: HIV-1 infected subjects who are presently failing an antiretroviral therapy regimen containing lamivudine or emtricitabine, genotypically demonstrate a MI84V variant, and have an HIV RNA plasma level ≥ 2,000 and ≤ 150,000 copies/mL. Study Design: HIV-1 infected subjects, with a documented M184V variant, will be randomized to receive elvucitabine 10 mg QD or lamivudine 300 mg QD for 14 days. Subjects must be receiving a stable antiretroviral regimen (defined as no change in antiretroviral therapy for at least 4 weeks prior to randomization) that includes lamivudine or emtricitabine. At 72 hours prior to randomization, only lamivudine or emtricitabine will be stopped for washout; subjects will continue to receive the other drugs in their prescribed regimen (background antiretroviral therapy) during the ...
lamivudine and zidovudine - description, side Effects of lamivudine and zidovudine, dosage (lamivudine and zidovudine), proper use of lamivudine and zidovudine. Drugs review.
Moderate inhibitors of CYP3A4 (erythromycin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem) increase the level of dapoxetine systemic exposure! DOJ/CRD continues to use its traditional fair housing tools to prevent segregation and re-segregation of communities? While there are men who come and complain that their partners are not participating in a sexual act the way they want them to, efavirenz lamivudine tenofovir price there are a variety of reasons why women dont. After the threshold of the motor endplate is reached, efavirenz lamivudine tenofovir price the muscle membrane is depolarized and excitation-contraction coupling is initiated? Discover parrot-fashion pulmicort buy the ghd ® Official Website ghdhaircom for the latest ghd! (152) The court also reiterated its prior reliance on peer review noting that no scientific or medical journal had published plaintiffs experts studies! Im bookmarking and will be tweeting this to my followers? ...
With acetaminophen, compared badly with a placebo, plasma lamivudine concentrations were highly significantly increased deviations from 15 to 120 min. About 15 years ago, members of the Abacavir and lamivudine international study group conducted two studies in which they examined the effectiveness of lamivudine. Part ii summary of product quality characteristics 1 name of the medicinal product Trizivir injection 250,000 iu 2 qualitative and quantitative elementary composition each vial which contains lamivudine 250
Search Indian Lamivudine Tablets Manufacturers and Suppliers Details - Contact to Lamivudine Tablets Exporters in India, Lamivudine Tablets Wholesalers, Lamivudine Tablets Distributors and Traders from India.
This product is used in monitoring and controlling of impurity levels in Lamivudine and its related formulations as per ICH formulated guidelines. Find out impurities of Lamivudine developed by our R&D. Synonyms: trans-Lamivudine; Lamivudine 5-Epimer. Find out PRICE, STOCK, Lead Time & shipping of 5-Epi Lamivudine. Available in packs as per your requirement!
Lamivudine Solution - description, side Effects of Lamivudine Solution, dosage (Lamivudine Solution), proper use of Lamivudine Solution. Drugs review.
Cheapest Lamivudine available online! Anyone Order Lamivudine Online, Non Prescription Lamivudine Cheap ... store can buy lamivudine over counter
Dr Lenna Martyak and colleagues from California, USA determined the effect of lamivudine prophylaxis on the rate of Hepatitis B viral reactivation.. The research team also determined the overall survival and Hepatitis B viral reactivation-related survival in patients with Hepatitis B viral undergoing chemotherapy.. A comprehensive search of MEDLINE, Cochrane Collaboration Database, reference lists, and abstracts from national meetings was undertaken.. The team performed statistical analysis using revman.. The researchers found that 11 studies met the defined inclusion criteria, and included these in the analysis.. Lamivudine prophylaxis was received by 220 patients, and 400 did not receive prophylaxis.. The team found that patients given lamivudine prophylaxis had a 87% decrease in Hepatitis B viral reactivation.. The number needed to treat to prevent 1 reactivation was 3.. The team found that the lamivudine prophylaxis group was also associated with a 70% reduction in reactivation-related ...
Lamivudine is a nucleoside analog with activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Patients coinfected with HIV and HBV may have hepatitis flares when lamivudine therapy is discontinued or when resistance of HBV to lamivudine emerges. This retrospective, descriptive study conducted in three tertiary care medical centers describes patients coinfected with HIV type 1 and HBV who presented with a spectrum of clinical and subclinical hepatitic responses to lamivudine withdrawal or resistance. One patient had fulminant hepatic failure and a second patient had subclinical hepatitis when lamivudine therapy was discontinued and a more efficacious antiretroviral regimen was substituted. Three patients had flares of hepatitis after 13 to 18 months of lamivudine therapy. Lamivudine withdrawal or emergence of lamivudineresistant mutants in patients coinfected with HIV and HBV may result in severe hepatitis. Clinicians caring for patients with coinfection with HIV and HBV ...
Buy online Abacavir lamivudine Tablets, We SAINTROY LIFESCIENCE are one of the ISO 9001:2008 Certified leading supplier, exporter, Manufacturer, distributor and trader of Abacavir lamivudine Tablets based in Surat, Gujarat, India
A chronic infection with hepatitis B virus (HBV) results in substantial morbidity and mortality worldwide, claiming up to 1 million deaths annually.1 Chronic hepatitis B (CHB) can be a silent disease for decades, but cirrhosis, liver failure, and hepatocellular carcinoma (HCC) can be the result of untreated infection.2,3 Lamivudine (LAM) is the first nucleoside analog approved for treatment of CHB, and has been applied globally for CHB patients. But LAM is associated with the highly frequent emergence of drug-resistant mutants, the cumulative rate is about 20% per year.4,5 LAM and Adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM resistant CHB patients. The American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL) and the Korean Association for the Study of the Liver (KASL) guidelines recommend combination therapy for treatment of LAM resistant CHB patients.6-8 Lampertico et al reported a ...
Buy online Lamivudine and Zidovudine Tablets, We SAINTROY LIFESCIENCE are one of the ISO 9001:2008 Certified leading supplier, exporter, Manufacturer, distributor and trader of Lamivudine and Zidovudine Tablets based in Surat, Gujarat, India
In this study, all the patients have been treated with nucleotide analogues for a long term, in which three with telbivudine and three with lamivudine. The causal link between the development of myopathy and nucleotide analogues administration was clear and convincing. All patients developed their symptoms after the long-term administration of the analogues, and no alternative cause can be found. Muscle weakness and limb numbness improved after the change or discontinuation of the drugs without special management except patient 5 who continued oral lamivudine. Three patients in this retrospective study changed the treatment to entecavir, and muscle strength improved to normal as well. More importantly, with the administration of entecavir, no extra time was needed for these three patients to restore their normal muscle power compared with the two patients who discontinued the nucleotide analogue therapy. This experience suggests that lamivudine/telbivudine-associated neuromyopathy can be cured ...
Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-817 ...
This product is used in monitoring and controlling of impurity levels in Lamivudine and its related formulations as per ICH formulated guidelines. Find out impurities of Lamivudine developed by our R&D. Synonyms: (S,R)-4,4-(Methylenebis(azanediyl))bis(1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one); . Find out PRICE, STOCK, Lead Time & shipping of Lamivudine Dimer. Available in packs as per your requirement!
We are looking for new customers to provide them with 10 percent discount for medications!. Buy Lamivudine Online! ,, ENTER HERE!. Cheapest prices for Lamivudine Guaranteed. Fast Guaranteed Worldwide Delivery. The Most Trusted Online Drug Supplier. No Prescription Required. Accept: Visa/MasterCard/eCheck/Amex/Bitcoin ...
BACKGROUND:: The M184V mutation decreases the replication capacity of HIV-1. This prospective study aimed to characterize the virologic and immunologic changes during monotherapy with lamivudine (3TC) in patients with limited options for a fully suppressive new therapy. METHODS:: Clinically stable patients with CD4 cells greater than 300/muL, previous virologic failure, and a M184V mutation were treated with 3TC 300 mg once daily during 48 weeks. The primary study endpoint was time to CD4 cell decrease by 30% or to below 200 cells/muL. RESULTS:: Patients were switched from either a protease inhibitor (PI)-containing highly active antiretroviral therapy (PI group, N = 10) or from reverse transcriptase (RT) inhibitor regimens (RT group, N = 16). Among all 26 patients with a median baseline HIV-1 RNA of 3866 copies/mL and CD4 cell count of 432/muL, the probability of reaching the endpoint after 12, 24, 36, and 48 weeks was 15%, 36%, 57%, and 70%, respectively. The median time to the endpoint was ...
Order Abacavir/Lamivudine/Zidovudine 150mg/300mg/300mg (generic equivalent to Trizivir) 60 tablets online, including Abacavir/Lamivudine/Zidovudine
Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking. Time to treatment discontinuation (TD) and virological failure (VF) were compared in a cohort of HIV+ patients on a virologically-effective ART starting lamivudine with either darunavir/r, atazanavir/r or dolutegravir. Changes in laboratory parameters were also evaluated. Four-hundred-ninety-four patients were analyzed (170 switching to darunavir/r, 141 to atazanavir/r, 183 to dolutegravir): median age was 49 years, with 8 years since ART start. Groups differed for age, HIV-risk factor, time since HIV-diagnosis and on ART, previous therapy and reasons for switching. Estimated proportions free from TD at week 48 and 96 were 79.8 and 48.3% of patients with darunavir/r, 87.0 and 70.9% with atazanavir/r, and 88.2 and 82.6% with dolutegravir, respectively (p | 0.001). Calendar years, HIV-risk factor, higher baseline cholesterol and an InSTI
Lamivudine + stavudine is used in the treatment of .get complete information about lamivudine + stavudine including usage, side effects, drug interaction, expert advice along with medicines associated with lamivudine + stavudine at 1mg.com
BACKGROUND Delta virus (HDV)-related chronic hepatitis is difficult to treat. AIMS To evaluate the efficacy of lamivudine 100 mg daily on serum HDV-RNA, hepatitis D virus antibodies and alanine aminotransferase levels, liver histology, and on hepatitis B surface antigen seroconversion. METHODS Thirty-one hepatitis B surface antigen-positive, HDV-RNA-positive patients with ALT | or = 1.5 upper normal level and compensated liver disease were randomized (1:2 ratio) to placebo (group A, n = 11) or lamivudine (group B, n = 20) for 52 weeks; thereafter, all patients were given lamivudine for 52 weeks and followed up for 16 weeks. RESULTS Twenty-five patients (81%) completed the study. No patient was HDV-RNA-negative at week 52; three patients (11%) were negative at week 104. Two of them remained HDV-RNA-negative at week 120, and one lost the hepatitis B surface antigen without seroconversion. Paired pre-treatment and week 104 liver biopsies were available from 19 patients: of which three of seven (43%)
The addition of adefovir dipivoxil (ADV) to ongoing lamivudine therapy is effective against lamivudine-resistant virus in patients with hepatitis B virus (HBV) infection. We studied 39 patients who received ADV added to lamivudine for breakthrough hepatitis. We determined early viral changes (12 wee …
Two large phase III trials comparing treatment with telbivudine and lamivudine over a 2-year period were conducted in adult patients with CHB. The GLOBE study (NV-02B-007, 007 ), conducted in 20 countries, compared these two antiviral agents in 1367 (921 HBeAg-positive) patients.6 A similarly designed study (NV-02B-015, 015 ) was conducted in China and enrolled 332 (290 HBeAg-positive) patients.7 In both studies, treatment with telbivudine for 2 years demonstrated significantly greater antiviral effects, compared with lamivudine, in both HBeAg-positive and HBeAg-negative patients ...
Amitriptyline in een creme geeft zelden bijwerkingen bij juist gebruik. These symptoms can be easily attributed to other conditions, such as excessive coffee drinking, aging, stress, excessive exercise, lack of exercise. Valid for up to a 365-day supply per calendar year! Although easier to carry out, this test has also not been validated; in retrospective studies, it performed about as well as the four-glass method! However, lamivudine oral solution it will not cure angular cheilitis that is caused by fungus! And though that wasnt the frequency I preferred, lamivudine price in nigeria I got used to it, and feel that. [58] flatulently ayur slim tablet price [82] Concerts performed at Madison Square Garden in New York City were filmed for an HBO television special titled Lady Gaga Presents the Monster Ball Tour: At Madison Square Garden? Long-term immunomodulating therapies may predispose patients with MG to various complications? Other blandly benzac ac 2.5 gel price in india non-beverage ...
This trial will evaluate the long-term outcomes of entecavir and lamivudine therapy in patients with chronic hepatitis B infection, who have enrolled in
Corresponding author. Mailing address: Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Phone: 81-82-257-5190. Fax: 81-82-255-6220. E-mail: chayama{at}hiroshima-u.ac.jp ...
Lamivudine + Nevirapine + Zidovudine- ਵਰਤੋਂ, ਖੁਰਾਕ, ਬੁਰੇ ਪ੍ਰਭਾਵ, ਲਾਭ, ਪਰਸਪਰ ਪ੍ਰਭਾਵ ਅਤੇ ਚੇਤਾਵਨੀ ਦੇਖੋ
ABSTRACT. An 18 years old male patient with history of RVD (+ve) on ART reported generalized weakness, body pains, head ache, and loose motions 3 episodes since one week. Acute pancreatitis due to anti-retro viral therapy was diagnosed. Lamivudine was most probable causal agent. Pancreatitis was confirmed by ultra sound scan of abdomen.. Keywords: Lamivudine, Pancreatitis, Anti-retro viral therapy, Patient care.. ...
This trial investigated the antiviral activity and safety of entecavir versus lamivudine in adults with chronic hepatitis B infection who are negative for
Buy Lamivudine zidovudine - Combivir, Epivir, Retrovir. Acheter Medicament Sans Ordonnance en ligne en Suisse, en France, en Belgique.
Chronic hepatitis B infection can lead to cirrhosis, hepatic failure, and hepatocellular carcinoma. Current therapies are successful in a minority of patients. Approximately 19 percent of patients respond to interferon alfa, and 10 to 15 percent respond to lamivudine (Epivir). The long-term efficacy of current agents may be worse. For lamivudine, viral resistance is reported in more than one half of patients within three years. Janssen and colleagues reasoned that the combination of interferon alfa and lamivudine in a long-term treatment regimen could improve sustained response rates in chronic hepatitis B infection.. The authors conducted a randomized, double-blind controlled trial at 42 centers in 15 countries to compare the safety and effectiveness of interferon alfa monotherapy with combination therapy using interferon alfa plus lamivudine. Participants were at least 16 years of age and had been positive for hepatitis B surface antigen for at least six months. In the eight weeks before ...
Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant. We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with undetectable plasma HIV-1 viral load (pVL), performing a time to loss of virological response (TLOVR ,50copies/mL) and a snapshot analysis at 48, 96, and 144 weeks. Virological failure (VF) was defined as confirmed pVL ,50copies/mL. We included 285 subjects, 67% male, with median baseline CD4 530 cells, and 44 months with pVL ≤50copies/mL. The third drug in the previous regimen was ritonavir-boosted atazanavir (ATV/r) in 79 (28%), and another ritonavir-boosted protease inhibitor (PI/r) in 29 (10%). Ninety (32%) had previously failed with a PI. Proportions of people with virological success at 48/96/144 weeks were 90%/87%/88% (TLOVR) and 74%/67%/59% (snapshot analysis), respectively. The rates of VF were 8%/8%/6%. Rates of adverse events leading to ...
In this study, we investigated the antiviral efficacy of TDF monotherapy versus combination therapy with TDF plus LAM or LdT in patients infected with HBV variants resistant to LAM using IPTW. The probability of achieving complete virologic suppression was 89% after 12 months of TDF monotherapy, indicating that TDF alone has excellent antiviral efficacy in LAM-resistant patients. TDF plus LAM or LdT combination therapy did not demonstrate superior efficacy over TDF monotherapy in viral suppression before and after adjustment for treatment selection bias using IPTW. Overall, TDF monotherapy and TDF plus LAM or LdT combination therapy were safe and well tolerated, without significant renal events or myopathy.. This is the largest study to compare the efficacy and safety of TDF monotherapy with TDF plus LAM or LdT combination therapy in CHB patients with documented LAM resistance. In a small prospective open-label study that assessed the efficacy of TDF monotherapy or TDF plus LAM combination ...
Background: Provision of antiretroviral therapy has expanded in Sub-Saharan Africa and quality assurance of antiretrovirals is of crucial importance for the success of treatment programmes. Therefore WHO, in co-operation with national authorities, organized a quality survey of antiretrovirals in selected African countries. Methods: The survey was performed in Cameroon, the Democratic Republic of Congo, Kenya, Nigeria, United Republic of Tanzania, Uganda and Zambia. Country teams made up of WHO country officers and national authority representatives collected samples at public and private sector antiretroviral procurement organizations and treatment centres around the capital cities. Samples included monocomponent products of didanosine, efavirenz, lamivudine, nevirapine, stavudine and zidovudine, and fixed-dose combinations of lamivudine/zidovudine, stavudine/lamivudine, stavudine/lamivudine/nevirapine. All samples were tested by the Official Medicines Control Laboratory of Switzerland, ...
Patients with drug-resistant CHB have a poor prognosis compared to patients without drug resistance [13]. Recently, the risk of developing NA-resistant mutations has decreased in treatment-naïve patients after widespread use of highly potent antiviral agents with high genetic barriers, such as entecavir and TDF [5,8]. A recent study showed that the efficacy of TDF was preferable to entecavir for achieving CVS in NA-experienced CHB patients without genotypic resistance, which suggests that previous antiviral treatment has clinical implications regarding the selection of an antiviral agent irrespective of preexisting genotypic resistance [14]. Likewise, our previous study showed that prior treatment with low-potency lamivudine affected the long-term efficacy of entecavir, even without genotypic resistance to lamivudine [4]. Drug-resistant mutations developed from previously used drugs are preserved in covalently closed circular DNA in the liver, and these mutations might attenuate the efficacy of ...
ORCID: 0000-0002-3670-6588 (2017) Risk of hepatitis B virus (HBV) infection and re-activation after discontinuation of tenofovir and/or lamivudine as part of antiretroviral therapy in a high HBV endemicity setting. . ...
As a whole, 122 well-treated patients (mean age, 45.2 years; mean CD4 T + lymphocyte count, 589 cells/mm3; mean duration of current cART, 3.1 years) were enrolled. Current antiretroviral regimen included tenofovir/emtricitabine in 91 subjects, abacavir/lamivudine in 25, lopinavir/r in 41, DRV/r in 38 and ATV/r in 33. Baseline mean estimated glomerular filtration rate (eGFR) was 94.2 mL/min/1.73 m2, and proteinuria was detected in 46 subjects (38%). Overall 70 subjects switched to 3TC + DRV/r (group A) and 52 to 3TC + ATV/r (group B). After 12 months, 65 patients (92.8%) in group A and 46 (88.4%) in group B showed HIV RNA ...
Abacavir sulfate, lamivudine and zidovudine carries a standard black box opens warning against paediatric use as a result strictly of its zidovudine content. In addition, there is no explanation for why there is a high incidence of hives or welts in children treated with prescription of medicine. At this time she said she believed she had chosen right arm hives or welts due physiologi
Micro Labs Limited: Lamivudine, nevirapine, and zidovudine tablets is indicated alone as a complete regimen or in combination with other antiretrovirals for...
LAMIVUDINE (3TC) 7. NELFINAVIR 8. NEVIRAPINE 9. RITONAVIR 10. SAQUINAVIR 11. ZALCITABINE (ddC) 12. ZIDOVUDINE (AZT) 1. ...
3TC is also called lamivudine. From 1998 to 2000, Wainberg was President of the International AIDS Society. He was Co-Chair of ...
... is a class of prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified doctor.The manufacture and sale of all drugs are covered under the Drugs and Cosmetics Act and Rules. It is revised at times based on the advice of the Drugs Technical Advisory Board, part of the Central Drugs Standard Control Organization[1] in the Ministry of Health and Family Welfare. The most recent schedule H (2006) lists 536 drugs from abacavir to zuclopenthixol.[2] However, enforcement of Schedule H laws in India is lax, compared to the more restrictive Schedule X, for which a mandatory documentation trail must be maintained.[3] ...
Lamivudine/zidovudine. Medicines for prevention of HIV-related opportunistic infections[edit]. *Isoniazid/pyridoxine/ ...
Lamivudine was the first approved oral nucleoside analogue. While effective and potent, lamivudine has been replaced by newer, ... Lamivudine as a single treatment is contraindicated in patients coinfected with HIV, as resistance develops rapidly, but it can ... Lamivudine is generally safe and well tolerated. Many patients develop resistance, which is correlated with longer treatment ... It is preferred to adefovir both in lamivudine-resistant patients and as initial treatment since it is both more potent and ...
Lamivudine is not toxic to mitochondria in vivo. Individuals who had been taking didanosine combined with stavudine exhibited ... 1997). "Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B." Hepatology. 26 ( ... Lamivudine has reverse chirality compared to didanosine, stavudine, zidovudine, and natural nucleosides. Mitochondrial DNA ... 2008). "Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial ...
Lamivudine/raltegravir, a combination with lamivudine, is also available. Raltegravir was initially approved only for use in ...
Other examples include 2-hydroxytetrahydrothiophene and the anti-HIV drug Lamivudine. Another class of isolable hemithioacetals ... "Enantioselective enzymatic synthesis of the anti-viral agent lamivudine (3TC™)". Tetrahedron Letters. 36 (38): 6961-6964. doi: ...
Lamivudine, also called 3TC, has the trade name Zeffix and Epivir. It is approved for the treatment of both HIV and hepatitis B ... Sarafianos, SG; Das, K; Clark Jr, AD; Ding, J; Boyer, PL; Hughes, SH; Arnold, E (1999). "Lamivudine (3TC) resistance in HIV-1 ... It is also used in a combination tablet as doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo). This is a new class ... Emtricitabine, also called FTC, has the trade name Emtriva (formerly Coviracil). Structurally similar to lamivudine, it is ...
2007) Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. AAPS Pharm Sci Tech., 21;8: E111. Mao X, ...
2',3'-dideoxy-3'-thiacytidine (lamivudine, 3TC) was discovered by Bernard Belleau. The history of lamivudine can be traced back ... Lamivudine was developed as the sulfur analogue of zalcitabine (see table 2). It was initially synthesized as a racemic mixture ... Lamivudine is the negative enantiomer and is a pyrimidine nucleoside analogue. The 3' carbon of the ribose ring of 2'- ... It is similar in many ways to lamivudine and is active against both HIV-1 and hepatitis B virus (HBV). Carbocyclic analogues of ...
Mark Wainberg, 71, Canadian medical researcher, co-discoverer of lamivudine, asthma. Sheila Abdus-Salaam, 65, American judge, ...
Abacavir/dolutegravir/lamivudine, a combination with abacavir and lamivudine is also available. As of 2019, the World Health ...
March 2006). "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B." N. Engl. J. Med. 354 (10): 1001 ... 9 March 2006). "Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B". The New England Journal of ... August 2002). "Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases ... June 2006). "Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B". Gastroenterology. 130 (7): ...
One patent covers compounds intended to treat hepatitis B in synergy with lamivudine; another relates to recyclable packaging ...
Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R (February 2008). "Lamivudine prevents reactivation of hepatitis B ... Gan SI, Devlin SM, Scott-Douglas NW, Burak KW (October 2005). "Lamivudine for the treatment of membranous glomerulopathy ... These include antiviral medications lamivudine, adefovir, tenofovir disoproxil, tenofovir alafenamide, telbivudine, and ...
In 1992, they first published on lamivudine (3TC) in Antimicrobial Agents and Chemotherapy. This drug became one of the most ... Lamivudine, and Telbivudine. In 2018, Schinazi received the Chevalier de la Légion d'honneur, the French Legion of Honor, with ...
Due to its known safety profile and extensive use in pregnant patients, zidovudine-lamivudine is the preferred choice as the ... For women who are coinfected with hepatitis B, tenofovir with either emtricitabine or lamivudine is the preferred NRTI backbone ... Premature newborns should only receive zidovudine, lamivudine, and/or nevirapine based on toxicity testing. Newborns who were ...
2007). "Telbivudine versus lamivudine in patients with chronic hepatitis B". N Engl J Med. 357 (25): 2576-88. doi:10.1056/ ... 2005). "A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic ... Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause ...
It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine. It can be used by mouth or ... AZT has been used for post-exposure prophylaxis (PEP) in combination with another antiretroviral drug called lamivudine. ...
Tyrrell's research into viral hepatitis lead to the development of the oral antiviral drug lamivudine. This treatment enabled ...
It is structurally related to lamivudine and emtricitabine, and, like these, is an analogue of cytidine. It was first developed ... In vitro, apricitabine is effective against NRTI-(lamivudine and zidovudine)-resistant virus strains, including M184V and ... and upper respiratory infection-similar to those of lamivudine; apricitabine was not associated with abnormal lipase levels, ... results from simultaneous provision of the drug alongside two other marketed drugs when compared to those drugs with lamivudine ...
It is very similar to lamivudine (3TC) and cross-resistance between the two is near-universal.[medical citation needed] US ...
AZT plus lamivudine or AZT plus lamivudine plus indinavir. Just like Study 035, patients couldn't be in the study if they had ... 97 patients were randomly assigned to one of the three groups: indinavir monotherapy, AZT and lamivudine, or all three agents. ... September 1997). "Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection ... and none of the thirty patients in AZT and lamivudine group got below 500 copies. This study took a look at clinical efficiency ...
... and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy". New England Journal of ...
"High throughput LC-MS/MS method for simultaneous quantification of lamivudine, stavudine and nevirapine in human plasma". ...
The main benefit of adefovir over lamivudine (the first NRTI approved for the treatment of HBV) is that it takes a much longer ... "Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine". ...
Rudin D, Shah SM, Kiss A, Wetz RV, Sottile VM (November 2007). "Interferon and lamivudine vs. interferon for hepatitis B e ... The treatment of chronic carriers of the hepatitis B virus by using a similar strategy using lamivudine has been developed. ... Examples of nucleoside analogues are aciclovir for Herpes simplex virus infections and lamivudine for HIV and hepatitis B virus ... They are susceptible to antiviral drugs that inhibit the reverse transcriptase enzyme, e.g. zidovudine and lamivudine. An ...
... and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy". The New England Journal ...
"A phase II open-label exploratory study of saquinavir in combination with zidovudine and lamivudine in HIV-infected patients ... in addition to providing clinical data leading to FDA approval of lamivudine, indinavir, ritonavir and saquinavir.[citation ...
Abacavir/dolutegravir/lamivudine, tradename Triumeq. References[edit]. *^ a b c d e f g h i "Abacavir and Lamivudine Tablets". ... "Abacavir + Lamivudine". International Drug Price Indicator Guide. Retrieved 28 November 2016.. *^ Hamilton, Richart (2015). ... Abacavir/lamivudine, sold under the brand name Kivexa among others, is a medication used to treat HIV/AIDS.[1] It is a fixed ... Abacavir/lamivudine was approved for medical use in the United States in 2004.[1] It is on the World Health Organizations List ...
Lamivudine: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Lamivudine comes as a tablet and oral solution (liquid) to take by mouth. Lamivudine (Epivir) is usually taken once or twice a ... Lamivudine controls HIV and hepatitis B infection and but does not cure them. Continue to take lamivudine even if you feel well ... Before taking lamivudine,. *tell your doctor and pharmacist if you are allergic to lamivudine, any other medications, or any of ...
... abacavir and lamivudine. These are both medicines called nucleoside reverse transcriptase inhibitors (NRTIs). They are used in ... Kivexa (abacavir, lamivudine). Kivexa tablets contain two active ingredients, abacavir and lamivudine. These are both medicines ... Epivir contains just lamivudine.. Triumeq contains abacavir and lamivudine in combination with another anti-HIV medicine called ... Abacavir and lamivudine work by blocking the action of this enzyme, thereby interfering with the conversion of viral RNA into ...
Blood levels of lamivudine may be increased by bactrim or septra. See Fact Sheet 535 for more information on these drugs. ... The dosage of lamivudine should be reduced for people who weigh less than 50 kilograms (110 pounds). People who weigh less than ... Some people with HIV had their hepatitis B get worse after they stopped taking lamivudine, a part of Combivir. Get tested for ... Also, lamivudine and emtricitabine (FTC) are very similar and should not be taken together. ...
Lamivudine and Tenofovir: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Continue to take lamivudine and tenofovir even if you feel well. Do not stop taking lamivudine and tenofovir without talking to ... Before taking lamivudine and tenofovir,. *tell your doctor and pharmacist if you are allergic to lamivudine, tenofovir, any ... If you have HBV and you take lamivudine and tenofovir, your condition may suddenly worsen when you stop taking lamivudine and ...
Do not prescribe lamivudine/zidovudine, abacavir/lamivudine, or abacavir/lamivudine/zidovudine to patients taking emtricitabine ... Abacavir/lamivudine (with abacavir) Abacavir/lamivudine/zidovudine (with zidovudine and abacavir) "Lamivudine". The American ... Lamivudine may be included as part of post-exposure prevention in those who have been potentially exposed to HIV. Lamivudine is ... As a result, lamivudine was identified as a less toxic agent to mitochondria DNA than other retroviral drugs. Lamivudine was ...
Lamivudine is a very rare cause of clinically apparent drug induced liver injury, but is associated with flares of underlying ... Lamivudine is a nucleoside analogue and reverse transcriptase inhibitor used in the therapy of human immunodeficiency virus ( ... NIH Case: Lamivudine D6]. A 43 year old man with HBeAg-positive chronic hepatitis B was started on lamivudine (100 mg daily) ... Lamivudine was approved by the FDA for HIV infection in 1995 and for HBV infection in 1998. Lamivudine is currently used in ...
Blood levels of lamivudine may be increased by bactrim or septra. See Fact Sheet 535 for more information on these drugs. ... The dosage of lamivudine should be reduced for people who weigh less than 50 kilograms (110 pounds). People who weigh less than ... Some people with HIV had their hepatitis B get worse after they stopped taking lamivudine, which is part of Trizivir. Get ... The most common side effects of Trizivir are the same as with the drugs it contains: zidovudine, lamivudine and abacavir. They ...
Helping you find trustworthy answers on Lamivudine , Latest evidence made easy ... Find all the evidence you need on Lamivudine via the Trip Database. ... Lack of Effect of Lamivudine on Ebola Virus Replication (Full text). Lack of Effect of Lamivudine on Ebola Virus Replication ... Increasingly, lamivudine is being used to prevent hepatitis B reactivation. To assess the effects of prophylactic lamivudine on ...
... is an antiviral medicine that prevents human immunodeficiency virus (HIV) or hepatitis B virus from multiplying in ... What other drugs will affect lamivudine?. Other drugs can affect lamivudine, and some drugs should not be used at the same time ... Children who weigh more than 30 pounds (14 kilograms) should use the tablet form of lamivudine if possible. Lamivudine liquid ... You may take lamivudine with or without food.. Lamivudine doses are based on weight in children. Your childs dose needs may ...
Serious side effects include emergence of lamivudine-resistant hepatitis B virus (HBV), severe acute exacerbations of HBV, ... dolutegravir and lamivudine) is a prescription medication used to treat HIV-1 infection in adults. ... What is Dovato (dolutegravir and lamivudine), and how does it work?. Dovato (dolutegravir and lamivudine) is a prescription ... Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported ...
A list of US medications equivalent to Lamivudine, Nevirapine and Stavudine is available on the Drugs.com website. ... Lamivudine, Nevirapine and Stavudine is a medicine available in a number of countries worldwide. ... Ingredient matches for Lamivudine, Nevirapine and Stavudine. Lamivudine. Lamivudine is reported as an ingredient of Lamivudine ...
The disclosure herein relates to a new Lamivudine polymorphic form, methods of making the same, and pharmaceutical formulations ... Preparation of Lamivudine Form I. A suspension of the Lamivudine (10.0) g in water (30.0 ml) was heated to 45° C. in 30 min to ... Preparation of Lamivudine Form III. A suspension of the Lamivudine form-II (25.0) g in water (75.0 ml) was heated to 45° C. in ... Preparation of Lamivudine Form III. A suspension of the Lamivudine form-II (20.0) g in water (60.0 ml) was heated to 45° C. in ...
Several companies now make generic versions of lamivudine. ... Lamivudine is a medication used to treat HIV, originally ... What is lamivudine?. Lamivudine is a medication used to treat HIV, originally marketed under the brand name Epivir. Several ... Lamivudine may be considered as an option for women who want to get pregnant, or who are pregnant. Lamivudine can sometimes ... How does lamivudine work?. Lamivudine is from a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). ...
... lamivudine, zidovudine) is a combination of antiviral medications that treat infections with the human immunodeficiency virus ( ... Trizivir (abacavir, lamivudine, zidovudine) Side Effects, Warnings, and Interactions. *What is Trizivir (abacavir, lamivudine, ... Lamivudine. Sorbitol. Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent ... What is Trizivir (abacavir, lamivudine, zidovudine)?. *What are the important side effects of Trizivir (abacavir, lamivudine, ...
Lamivudine, and Zidovudine. Includes indications, proper use, special instructions, precautions, and possible side effects. ... Abacavir, Lamivudine, and Zidovudine. Generic Name: Abacavir, Lamivudine, and Zidovudine (a BAK a veer, la MI vyoo deen, & zye ... It may not be safe to restart abacavir, lamivudine, and zidovudine. Throw away any of abacavir, lamivudine, and zidovudine that ... How is this medicine (Abacavir, Lamivudine, and Zidovudine) best taken?. Use abacavir, lamivudine, and zidovudine as ordered by ...
Lamivudine (3TC, Epivir) is an antiviral drug that reduces the amount of HIV in the body. Anti-HIV drugs such as lamivudine ... Lamivudine can be taken either with food or on an empty stomach. Once-daily dosing of lamivudine produces the same effects in ... Lamivudine is available as part of several co-formulations.. Lamivudine is co-formulated with zidovudine in one pill, known by ... Lamivudine European Working Group. JAMA, 276: 118-125, 1996.. Staszewski S et al. Safety and efficacy of lamivudine-zidovudine ...
LAMIVUDINE (UNII: 2T8Q726O95) (LAMIVUDINE - UNII:2T8Q726O95) LAMIVUDINE. 150 mg. ZIDOVUDINE (UNII: 4B9XT59T7S) (ZIDOVUDINE - ... Lamivudine and zidovudine tablets, USP are combination tablets containing lamivudine, USP and zidovudine, USP. Lamivudine ( ... Lamivudine: Lamivudine is a synthetic nucleoside analogue. Intracellularly, lamivudine is phosphorylated to its active 5- ... including lamivudine and zidovudine (components of lamivudine and zidovudine tablet). Discontinue lamivudine and zidovudine ...
... is a combination medicine used to treat HIV, which can cause the acquired immunodeficiency syndrome ( ... Abacavir and lamivudine are antiviral medicines that prevent human immunodeficiency virus (HIV) from multiplying in your body. ... What is abacavir and lamivudine?. Abacavir and lamivudine are antiviral medicines that prevent human immunodeficiency virus ( ... If youve ever had hepatitis B, it may become active or get worse after you stop using abacavir and lamivudine. You may need ...
Lamivudine ≥98% (HPLC), powder; CAS Number: 134678-17-4; Synonym: 2′,3′-Dideoxy-3′-thiacytidine, 3TC, Epivir, Epivir-HBV, ... Lamivudine ≥98% (HPLC), powder Synonym: 2′,3′-Dideoxy-3′-thiacytidine, 3TC, Epivir-HBV, Epivir, Heptovir, Zeffix ... Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). It is an analogue of cytidine, and can inhibit ...
Må kun anvendes under visse forudsætninger. Baggrund: Store epidemiologiske studier viser samstemmende, at antiretroviral behandling under graviditeten (for alle lægemidler og kombinationer er der data for i alt > 35.000 gravide; heraf > 16.000 eksponeret i 1. trimester) ikke er forbundet med en overhyppighed af medfødte misdannelser. Visse studier viser en lidt øget risiko for tidlig fødsel og lav fødselsvægt, men det er uklart, om og i hvilket omfang dette kan tilskrives behandlingen. For lamivudin er der data for over 4.500 1. trimester-eksponerede uden tegn på overhyppighed af uønsket fosterpåvirkning. Behandling af gravide med HIV-infektion er en specialistopgave. Se endvidere Midler mod HIV. Referencer: 4375, 4374, 4379, 4377, 4376, 4378 Se endvidere Klassifikation - graviditet. ...
Abacavir and lamivudine tablet contains the prescription medicines abacavir and lamivudine.. Abacavir and lamivudine tablets ... Lamivudine: Lamivudine is a synthetic nucleoside analogue. Intracellularly lamivudine is phosphorylated to its active 5′- ... Table 2. Pharmacokinetic Parametersa for Abacavir and Lamivudine in Adults Parameter Abacavir Lamivudine ... Lamivudine: Lamivudine did not affect male or female fertility in rats at doses up to 4,000 mg per kg per day, associated with ...
Abacavir dolutegravir, and lamivudine (Triumeq) is a combination medicine used to treat HIV, which causes the acquired ... and lamivudine are antiviral medications that prevent human immunodeficiency virus (HIV) cells from multiplying in your body. ... What is abacavir, dolutegravir, and lamivudine (Triumeq)?. Abacavir, dolutegravir, and lamivudine are antiviral medications ... Abacavir dolutegravir, and lamivudine (Triumeq) is a combination medicine used to treat HIV, which causes the acquired ...
... and lamivudine (Triumeq) is a combination medicine used to treat human immunodeficiency virus (HIV), the virus that can cause ... What is abacavir, dolutegravir, and lamivudine (Triumeq)?. What is abacavir, dolutegravir, and lamivudine (Triumeq)?. Abacavir ... What is the most important information I should know about abacavir, dolutegravir, and lamivudine (Triumeq)?. What is the most ... dolutegravir, and lamivudine (Triumeq) is a combination medicine used to treat human immunodeficiency virus (HIV), the virus ...
Find patient medical information for Abacavir-Dolutegravir-Lamivudine Oral on WebMD including its uses, side effects and safety ... If you have hepatitis B infection and HIV, you may have a serious worsening of hepatitis symptoms if you stop taking lamivudine ... Abacavir and lamivudine pass into breast milk. Because breast milk can transmit HIV, do not breast-feed. ... Your doctor will monitor liver tests for several months after you stop lamivudine. Get medical help right away if you develop ...
Drug: Atazanavir, ritonavir, lamivudine Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 ... Previous virological failure on a lamivudine- or PI-containing regimen or previous exposure to lamivudine-containing suboptimal ... Lamivudine is a well tolerated NRTI which showed no significant toxicity in the short and long term and, together with its ... Atazanavir/r + Lamivudine Dual Therapy (ATLAS). This study is ongoing, but not recruiting participants. ...
Find the most comprehensive real-world treatment information on Lamivudine-Zidovudine (3TC/ZDV) at PatientsLikeMe. 10 patients ... bipolar I disorder or psoriasis currently take Lamivudine-Zidovudine (3TC/ZDV). ... Showing 3 of 5 patient evaluations for Lamivudine-Zidovudine (3TC/ZDV) Previous page 1 2 Next page ...
Lamivudine (By mouth). Introduction. Lamivudine (la-MIV-ue-deen). Treats hepatitis B and HIV infection. This medicine will not ... Some foods and medicines can affect how lamivudine works. Tell your doctor if you are using interferon alfa or ribavirin. ... or other combination medicines that contain lamivudine. ...
  • Combivir is a pill that contains two drugs used as part of antiretroviral therapy (ART): zidovudine (Retrovir, AZT) and lamivudine (Epivir, 3TC). (thebody.com)
  • Each tablet includes 300 milligrams (mg) of zidovudine (Retrovir, AZT) and 150 mg of lamivudine (Epivir, 3TC). (thebody.com)
  • The most common side effects of Combivir are the same as with zidovudine (Retrovir) and lamivudine (Epivir). (thebody.com)
  • Lamivudine is also available in multiple fixed combinations with other antiretroviral agents such as zidovudine, abacavir, tenofovir, efavirenz, nevirapine, dolutegravir and others. (nih.gov)
  • Lamivudine is a rare cause of liver test abnormalities or clinically apparent liver injury in patients with HIV infection without hepatitis B. Although several instances of lactic acidosis with hepatic steatosis and liver failure have been reported in patients receiving lamivudine, in all instances other nucleoside analogues more clearly associated with mitochondrial injury [didanosine, stavudine, zalcitrabine, zidovudine] were also being taken. (nih.gov)
  • Do not prescribe lamivudine/zidovudine, abacavir/lamivudine, or abacavir/lamivudine/zidovudine to patients taking emtricitabine. (wikipedia.org)
  • Trizivir is a pill that contains three antiretroviral drugs (ARVs) used to fight HIV: zidovudine (Retrovir, AZT), lamivudine (Epivir, 3TC) and abacavir (Ziagen). (thebody.com)
  • The most common side effects of Trizivir are the same as with the drugs it contains: zidovudine, lamivudine and abacavir. (thebody.com)
  • Lamivudine and zidovudine are also available in a combination pill, originally marketed as Combivir . (aidsmap.com)
  • Trizivir ( abacavir, lamivudine, zidovudine ) is a combination of antiviral medications used for treating infections with the human immunodeficiency virus ( HIV ). (medicinenet.com)
  • What are the important side effects of Trizivir (abacavir, lamivudine, zidovudine)? (medicinenet.com)
  • Trizivir causes the same side effect as its component drugs, abacavir , lamivudine and zidovudine . (medicinenet.com)
  • Unsafe and sometimes deadly allergic effects with organ failure may happen with abacavir, lamivudine, and zidovudine. (drugs.com)
  • Do not restart abacavir, lamivudine, and zidovudine if you have had an allergic reaction. (drugs.com)
  • Do not take abacavir, lamivudine, and zidovudine if you have the HLA-B*5701 gene. (drugs.com)
  • Your doctor will check you for this gene before you start abacavir, lamivudine, and zidovudine. (drugs.com)
  • Hepatitis B has gotten worse when abacavir, lamivudine, and zidovudine was stopped in some people with hepatitis B. Close follow-up for a few months is needed when therapy is stopped in people who have hepatitis B. Do not stop taking abacavir, lamivudine, and zidovudine without calling your doctor. (drugs.com)
  • What do I need to tell my doctor BEFORE I take Abacavir, Lamivudine, and Zidovudine? (drugs.com)
  • Do not breast-feed while you take abacavir, lamivudine, and zidovudine. (drugs.com)
  • This is not a list of all drugs or health problems that interact with abacavir, lamivudine, and zidovudine. (drugs.com)
  • You must check to make sure that it is safe for you to take abacavir, lamivudine, and zidovudine with all of your drugs and health problems. (drugs.com)
  • What are some things I need to know or do while I take Abacavir, Lamivudine, and Zidovudine? (drugs.com)
  • Tell all of your health care providers that you take abacavir, lamivudine, and zidovudine. (drugs.com)
  • If abacavir, lamivudine, and zidovudine is stopped because you have an allergy to it, do not restart it. (drugs.com)
  • It may not be safe to restart abacavir, lamivudine, and zidovudine. (drugs.com)
  • Throw away any of abacavir, lamivudine, and zidovudine that you have not taken. (drugs.com)
  • If abacavir, lamivudine, and zidovudine is stopped for any other reason, do not restart it without talking to the doctor. (drugs.com)
  • Lamivudine is co-formulated with zidovudine in one pill, known by the trade name Combivir from ViiV Healthcare. (aidsmap.com)
  • Each Combivir pill contains 150mg lamivudine and 300mg zidovudine. (aidsmap.com)
  • A pill that combines 300mg zidovudine, 150mg lamivudine, and 300mg abacavir, known as Trizivir , is also available from ViiV Healthcare. (aidsmap.com)
  • NRTIs (also known as 'nukes') include abacavir, emtricitabine, lamivudine and zidovudine. (aidsmap.com)
  • These highlights do not include all the information needed to use Lamivudine and zidovudine tablets, USP safely and effectively. (nih.gov)
  • Lamivudine and zidovudine tablets, USP [150/300 mg] for oral use. (nih.gov)
  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including lamivudine and zidovudine (components of lamivudine and zidovudine tablets). (nih.gov)
  • Severe, acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine, a component of lamivudine and zidovudine tablets. (nih.gov)
  • Lamivudine and zidovudine tablets, USP a combination of 2 nucleoside analogue reverse transcriptase inhibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV - 1 infection. (nih.gov)
  • Because Lamivudine and zidovudine tablets, USP is a fixed-dose tablet and cannot be dose adjusted, lamivudine and zidovudine tablets are not recommended in patients requiring dosage adjustment or with hepatic impairment or experiencing dose-limiting adverse reactions. (nih.gov)
  • Lamivudine and zidovudine tablets, USP are contraindicated in patients with a previous hypersensitivity reactions to lamivudine or zidovudine. (nih.gov)
  • Discontinue lamivudine and zidovudine tablets as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. (nih.gov)
  • Most commonly reported adverse reactions (incidence greater than or equal to 15%) in clinical trials of combination lamivudine and zidovudine were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough. (nih.gov)
  • Read the side effects of Abacavir Sulfate, Lamivudine and Zidovudine as described in the medical literature. (medindia.net)
  • Abacavir Sulfate, Lamivudine and Zidovudine contains a nucleoside reverse transcriptase inhibitor (NRTI), prescribed for HIV-1 infection. (medindia.net)
  • What is the most important information I should know about lamivudine and zidovudine? (wellspan.org)
  • Your doctor may want to check your liver function for several months after you stop using lamivudine and zidovudine. (wellspan.org)
  • Lamivudine and zidovudine is a combination medicine used to treat HIV, which causes the acquired immunodeficiency syndrome (AIDS). (wellspan.org)
  • What should I discuss with my healthcare provider before taking lamivudine and zidovudine? (wellspan.org)
  • Some people develop a life-threatening condition called lactic acidosis while taking lamivudine and zidovudine. (wellspan.org)
  • Lamivudine and zidovudine can also cause severe or fatal liver problems. (wellspan.org)
  • Do not take Combivir with any other medicine that contains lamivudine, zidovudine, or emtricitabine. (wellspan.org)
  • This is to track the outcome of the pregnancy and to evaluate any effects of lamivudine and zidovudine on the baby. (wellspan.org)
  • Lamivudine and zidovudine should not be used to treat HIV in adolescents weighing less than 66 pounds. (wellspan.org)
  • How should I take lamivudine and zidovudine? (wellspan.org)
  • Lamivudine and zidovudine can be taken with or without food. (wellspan.org)
  • Lamivudine and zidovudine belong to a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). (canada.com)
  • Lamivudine and zidovudine are used in combination to treat HIV infection by preventing reverse transcriptase from working properly. (canada.com)
  • Each white to off-white, modified capsule-shaped, biconvex, film-coated tablets with deep breakline in between 'J' and '59' on one side and deep breakline on the other side, contains 150 mg of lamivudine and 300 mg of zidovudine. (canada.com)
  • The recommended dose for adults and adolescents 12 years of age and older is one tablet (150 mg of lamivudine and 300 mg of zidovudine) twice daily. (canada.com)
  • For adults weighing less than 30 kg (70 pounds), children below 12 years of age, and people with reduced kidney function, it is recommended that lamivudine and zidovudine be taken separately so each medication dose can be adjusted as needed. (canada.com)
  • Lamivudine - zidovudine may be taken with food or on an empty stomach. (canada.com)
  • The effectiveness of the medication depends on the right amount of lamivudine and zidovudine in the bloodstream. (canada.com)
  • Combivir is a combination of lamivudine (Epivir) and zidovudine (Retrovir), both components are active against the human immunodeficiency virus (HIV) and inhibit the activity of reverse transcriptase blocking the production of DNA and new viruses. (arfamed.com)
  • Separately zidovudine and lamivudine may not be so effective as their combination which makes it more difficult for HIV to produce high resistant strains. (arfamed.com)
  • Hypersensitivity to lamivudine or zidovudine. (arfamed.com)
  • To determine the clinical efficacy of indinavir sulfate or placebo in combination with zidovudine ( AZT ) and lamivudine ( 3TC ) in AIDS patients. (bioportfolio.com)
  • Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) with Efavi. (goldbamboo.com)
  • Combivir (Lamivudine / Zidovudine) is an antiviral combination used with other medicines to treat Human Immunodeficiency Virus (HIV) infection. (medformula.com)
  • To compare the safety and activity of lamivudine plus zidovudine with the safety and activity of zalcitabine plus zidovudine in patients with moderately advanced human immunodeficiency virus (HIV) infection who had received zidovudine. (annals.org)
  • In patients with HIV infection who had previously received zidovudine, 150 mg of lamivudine plus zidovudine resulted in greater immunologic evidence of benefit than did 0.75 mg of zalcitabine plus zidovudine and was better tolerated than 300 mg of lamivudine plus zidovudine. (annals.org)
  • Epivir contains a higher dose of lamivudine than Epivir-HBV. (medlineplus.gov)
  • Treatment with Epivir-HBV in patients infected with HIV may cause the HIV virus to be less treatable with lamivudine and other medicines. (medlineplus.gov)
  • Lamivudine (Epivir-HBV) is used to treat hepatitis B infection. (medlineplus.gov)
  • Lamivudine (Epivir-HBV) is usually taken once a day. (medlineplus.gov)
  • For HBV infection the recommended dose of lamivudine in adults is 100 mg orally once daily, the drug being available in this dose under the trade name Epivir-HBV. (nih.gov)
  • Lamivudine (Epivir HBV) is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. (wikipedia.org)
  • You should not take Epivir-HBV (for treating hepatitis B) if you also take other medicine that contains lamivudine or emtricitabine. (rexhealth.com)
  • What are the possible side effects of lamivudine (Epivir, Epivir HBV)? (emedicinehealth.com)
  • If you have HBV and you take lamivudine, your condition may suddenly worsen when you stop taking lamivudine. (medlineplus.gov)
  • Your doctor will examine you and order lab tests regularly for several months after you stop taking lamivudine to see if your HBV has worsened. (medlineplus.gov)
  • Do not stop taking lamivudine without talking to your doctor. (medlineplus.gov)
  • If you miss doses or stop taking lamivudine, your condition may become more difficult to treat. (medlineplus.gov)
  • If you stop taking lamivudine and tenofovir even for a short time, or if you skip doses, the virus may become resistant to medications and may be harder to treat. (medlineplus.gov)
  • If you have hepatitis B infection and HIV , you may have a serious worsening of hepatitis symptoms if you stop taking lamivudine. (webmd.com)
  • Do not stop taking lamivudine unless your doctor tells you otherwise. (rxwiki.com)
  • If you have hepatitis B infection along with HIV, your hepatitis symptoms may get worse or become very serious if you stop taking lamivudine. (kaiserpermanente.org)
  • Also, lamivudine and emtricitabine (FTC) are very similar and should not be taken together. (thebody.com)
  • We investigated the effect of combining the dolutegravir-specific R263K integrase resistance substitution with either M184I or M184V, two reverse transcriptase drug resistance substitutions that are frequently detected in individuals failing therapeutic regimens containing either lamivudine or emtricitabine. (tripdatabase.com)
  • Do not use this medicine together with zalcitabine, medicines containing emtricitabine, or other combination medicines that contain lamivudine. (umm.edu)
  • These mutations (rtM204V/I) confer cross-resistance to lamivudine, telbivudine, and other members that belong to the L-nucleoside structural group such as emtricitabine and clevudine and reduce susceptibility to entecavir [ 4 - 8 ]. (hindawi.com)
  • Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202. (sigmaaldrich.com)
  • ACTG A5202 randomized treatment-naïve individuals to tenofovir-emtricitabine (TDF/FTC) or abacavir-lamivudine (ABC/3TC) combined with efavirenz (EFV) or atazanavir/ritonavir (ATV/r). (sigmaaldrich.com)
  • Some people with HIV had their hepatitis B get worse after they stopped taking lamivudine, a part of Combivir. (thebody.com)
  • if you have ever had an allergic reaction to any medicine that contains abacavir or lamivudine (Combivir, Epivir, Triumeq, Trizivir, Ziagen). (rexhealth.com)
  • Aggravation of chronic liver disease hepatitis B is possible when treatment with Combivir is finished as its virus causative agent becomes resistant to lamivudine. (arfamed.com)
  • Take lamivudine exactly as directed. (medlineplus.gov)
  • Continue to take lamivudine even if you feel well. (medlineplus.gov)
  • Take lamivudine and tenofovir at around the same time every day. (medlineplus.gov)
  • You should not take lamivudine if you are allergic to it. (rexhealth.com)
  • How do I take lamivudine? (aidsmap.com)
  • You can take lamivudine with or without food. (aidsmap.com)
  • Do not take lamivudine if you are allergic to lamivudine or any of the ingredients of the medication. (medbroadcast.com)
  • Take lamivudine-HBV by mouth with or without food, usually once a day or as directed by your doctor. (kaiserpermanente.org)
  • tell your doctor and pharmacist if you are allergic to lamivudine, any other medications, or any of the ingredients in lamivudine tablets or oral solution. (medlineplus.gov)
  • Kivexa tablets contain two active ingredients, abacavir and lamivudine. (netdoctor.co.uk)
  • For HIV infection, lamivudine is available as 150 and 300 mg tablets and as oral solutions under the trade name Epivir. (nih.gov)
  • Lamivudine is also available in combination tablets. (aidsmap.com)
  • Tablets: 600 mg of abacavir and 300 mg of lamivudine. (nih.gov)
  • Please read this leaflet carefully before you start using Lamivudine RBX Tablets. (nps.org.au)
  • 150 mg lamivudine and 325.8 mg raltegravir potassium , equivalent to 300 mg raltegravir, green, oval-shaped, film-coated tablets with "144" on one side. (rxlist.com)
  • Triumeq® tablets contain 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine. (stjude.org)
  • Other import- ance of cannabis intoxication, mg2􏰃 3 267 abacavir sulfate and lamivudine tablets epzicom They should be measured by cYP2D6. (imagenenaccion.org)
  • abacavir sulfate and lamivudine tablets epzicom For heroin, given orally, clarithromycin are combined with androgens. (imagenenaccion.org)
  • A new simple, efficient, and sensitive reverse phase high performance liquid chromatographic method has been developed for simultaneously extraction and determination of the concentrations of lamivudine, tenofovir, darunavir and ritonavir in bulk and their tablets. (ijpsonline.com)
  • Lamivudine is a nucleoside analogue and reverse transcriptase inhibitor used in the therapy of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. (nih.gov)
  • Lamivudine is a nucleoside reverse transcriptase inhibitor and works by blocking the HIV reverse transcriptase and hepatitis B virus polymerase. (wikipedia.org)
  • Long-term use of lamivudine leads to emergence of a resistant hepatitis B virus (YMDD) mutant. (wikipedia.org)
  • Long-term use of lamivudine can trigger a resistant hepatitis B virus (YMDD) mutant. (wikipedia.org)
  • Lamivudine has been recommended as prophylaxis for the reactivation of hepatitis B virus (HBV) infection in patients undergoing chemotherapy. (tripdatabase.com)
  • Lamivudine is an antiviral medicine that prevents human immunodeficiency virus (HIV) or hepatitis B virus from multiplying in your body. (rexhealth.com)
  • Lamivudine is also active against hepatitis B virus (HBV). (aidsmap.com)
  • Lamivudine is a non-toxic, potent inhibitor of hepatitis B virus replication. (nih.gov)
  • Recently, hepatitis B virus resistance to lamivudine has been described in patients using immunosuppressive drugs after liver transplantation. (nih.gov)
  • The addition of adefovir dipivoxil (ADV) to ongoing lamivudine therapy is effective against lamivudine-resistant virus in patients with hepatitis B virus (HBV) infection. (nih.gov)
  • Lamivudine was the first approved inhibitor of hepatitis B virus (HBV) reverse transcriptase (RT). (asm.org)
  • Hepatitis B virus co-infection: monitor for post-treatment exacerbation, emergence of lamivudine-resistant HBV variants. (renalandurologynews.com)
  • Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient. (bioportfolio.com)
  • In lamivudine-refractory chronic hepatitis B (CHB) patients, discontinuation of lamivudine therapy may lead to loss of lamivudine-resistant hepatitis B virus (HBV) and reappearance of wide-type HBV as. (bioportfolio.com)
  • Lamivudine is a nucleoside analog reverse transcription inhibitor of HIV and hepatitis B virus that acts as a synthetic cytidine analog. (cdc.gov)
  • Lamivudine is also used to treat chronic hepatitis B virus infection. (rxwiki.com)
  • lamivudine/tenofovir disoproxil fumarate is a topic covered in the Davis's Drug Guide . (unboundmedicine.com)
  • Washington Manual , www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110597/0/lamivudine_tenofovir_disoproxil_fumarate. (unboundmedicine.com)
  • Vallerand AHA, Sanoski CAC, Quiring CC. Lamivudine/tenofovir disoproxil fumarate. (unboundmedicine.com)
  • If you are allergic to any of the HIV medicines in Cimduo (lamivudine and tenofovir disoproxil fumarate) or any other medicines. (thebodypro.com)
  • Lamivudine is currently used in many HAART regimens but is now rarely used to treat hepatitis B because of a high rate of antiviral resistance when it is used as monotherapy as well as the availability of more potent agents with a higher barrier to resistance. (nih.gov)
  • 50% and 90% inhibitory concentrations (IC50 and IC90) and corresponding antiviral resistance factors (RF50 and RF90) were calculated.The entecavir dose-response curve of lamivudine -resistant HBV RT mutants rtM204 for the replication of HBV decreased less than expected with increasing drug dose. (tripdatabase.com)
  • Lamivudine (3TC, Epivir ) is an antiviral drug that reduces the amount of HIV in the body. (aidsmap.com)
  • Abacavir and lamivudine are antiviral medicines that prevent human immunodeficiency virus (HIV) from multiplying in your body. (rexhealth.com)
  • Although patients with chronic hepatitis B developed hepatocellular carcinoma at a rate of 1.3 cases per 100 patient-years while receiving antiviral therapy, lamivudine resulted in significantly reduced incidence rates in a recent study. (healio.com)
  • Oral lamivudine (GlaxoSmithKline, Brentford, UK), a US Food and Drug Administration-approved anti-HIV drug, has been suggested as a possible antiviral agent against Ebola virus (EBOV). (cdc.gov)
  • However, given the recent testimonials regarding lamivudine effectiveness in treating EBOV-infected patients in Africa, we conducted additional studies to determine whether our previous assertion that lamivudine lacked any direct antiviral activity was correct. (cdc.gov)
  • No direct antiviral effect for lamivudine was observed at concentrations ≤320 µmol/L in Vero E6 cells ( Table ). (cdc.gov)
  • Finally, we assessed the antiviral activity of the compounds against a recent isolate prototype from the current outbreak, EBOV H. sapiens -tc/GIN/2014/Guéckédou-C05 (EBOV/Gue) to test whether inhibition of EBOV/Gue by lamivudine was different from that of the reference Kikwit strain. (cdc.gov)
  • In contrast to a known active compound (toremifene), lamivudine showed no direct antiviral activity. (cdc.gov)
  • The GLOBE study (NV-02B-007, 007 ), conducted in 20 countries, compared these two antiviral agents in 1367 (921 HBeAg-positive) patients.6 A similarly designed study (NV-02B-015, 015 ) was conducted in China and enrolled 332 (290 HBeAg-positive) patients.7 In both studies, treatment with telbivudine for 2 years demonstrated significantly greater antiviral effects, compared with lamivudine, in both HBeAg-positive and HBeAg-negative patients. (natap.org)
  • Lamivudine (Epivir) is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 3 months of age and older. (medlineplus.gov)
  • Lamivudine controls HIV and hepatitis B infection and but does not cure them. (medlineplus.gov)
  • Lamivudine is also used sometimes in combination with other medications to treat healthcare workers or other individuals exposed to HIV infection after accidental contact with HIV-contaminated blood, tissues, or other body fluids. (medlineplus.gov)
  • Lamivudine is indicated for the treatment of HBV infection as a single agent and for HIV infection in combination with other HIV medications. (nih.gov)
  • The recommended dose of lamivudine for HIV infection in adults is 150 mg twice daily or 300 mg once daily. (nih.gov)
  • Lamivudine was approved by the FDA for HIV infection in 1995 and for HBV infection in 1998. (nih.gov)
  • Lamivudine (Epivir) is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. (wikipedia.org)
  • Abacavir, dolutegravir, and lamivudine combination is used for the treatment of the infection caused by human immunodeficiency virus (HIV). (mayoclinic.org)
  • Abacavir, dolutegravir, and lamivudine combination will not cure or prevent HIV infection or AIDS. (mayoclinic.org)
  • LAMIVUDINE RBX is used together with other antivirals to slow down the progression of human immunodeficiency virus (HIV) infection, which can lead to Acquired Immune Deficiency Syndrome (AIDS) and other related illnesses (eg AIDS-related Complex or ARC). (nps.org.au)
  • On August 22, 2014, FDA approved a new fixed-dose combination product: TRIUMEQ, a combination of dolutegravir (integrase strand transfer inhibitor), abacavir sulfate and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) for the treatment of HIV-1 infection. (nih.gov)
  • Lamivudine is not a cure for HIV infection. (tradeindia.com)
  • A 100 mg formulation of lamivudine is also approved as a treatment for chronic hepatitis B infection. (catie.ca)
  • There are limited data on the use of lamivudine for patients with severe forms of acute hepatitis B. We report our experience with the use of lamivudine in six patients with acute HBV infection. (wiley.com)
  • Dovato is approved as a complete regimen for the treatment of HIV-1 infection in adults with no known antiretroviral treatment history and with no known substitutions associated with resistance to either dolutegravir or lamivudine. (positivelyaware.com)
  • The activity of lamivudine against EBOV infection was evaluated in a cell-based ELISA with 1995 isolate EBOV H. sapiens -tc/COD/1995/Kikwit (EBOV/Kik) ( 3 ). (cdc.gov)
  • Abacavir/Lamivudine contains two active ingredients that are used to treat HIV infection: abacavir and lamivudine. (medicines.org.uk)
  • Lamivudine is a prescription medication used to treat human immunodeficiency virus (HIV) infection. (rxwiki.com)
  • Lamivudine is a prescription medicine used to treat human immunodeficiency virus (HIV) infection and chronic hepatitis B infection virus infection in adults and children. (rxwiki.com)
  • Lamivudine is not cure for HIV infection or hepatitis B infection virus infection. (rxwiki.com)
  • Lamivudine-HBV contains a lower dose of the drug lamivudine, which is used to treat HIV infection as well as hepatitis B. Use of lamivudine-HBV in patients with unknown or untreated HIV infection could result in new types of HIV virus that are more difficult to treat (drug-resistant). (kaiserpermanente.org)
  • A lower-strength lamivudine product is used for hepatitis B infection in people without HIV infection. (kaiserpermanente.org)
  • Lamivudine is also co-formulated with abacavir and dolutegravir in the fixed-dose combination Triumeq . (aidsmap.com)
  • What is the most important information I should know about abacavir, dolutegravir, and lamivudine (Triumeq)? (cigna.com)
  • What is abacavir, dolutegravir, and lamivudine (Triumeq)? (cigna.com)
  • Abacavir dolutegravir, and lamivudine (Triumeq) is a combination medicine used to treat HIV, which causes the acquired immunodeficiency syndrome (AIDS). (cigna.com)
  • The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination of indinavir (IDV) plus stavudine (d4T) plus lamivudine (3TC) to HIV-infected children. (bioportfolio.com)
  • Both the GEMINI 1 & 2 studies showed that dolutegravir plus lamivudine continued to offer non-inferior efficacy to dolutegravir plus TDF/FTC at Week 96. (biospace.com)
  • Across both studies, 11 participants (1.5%) on dolutegravir plus lamivudine and seven (1.0%) on dolutegravir plus TDF/FTC met protocol-defined virologic withdrawal criteria through to Week 96. (biospace.com)
  • Pedro Cahn, M.D., principal investigator for the GEMINI study programme , said: "The Week 96 data from the GEMINI studies demonstrate that the clinical benefits of dolutegravir plus lamivudine we saw at Week 48 are sustainable, allowing us to use these two drugs while still getting efficacy non-inferior to that of a dolutegravir-based 3-drug regimen. (biospace.com)
  • Consistent with Week 48 outcomes, the response rate remained lower in dolutegravir plus lamivudine participants with CD4+ ≤ 200 cells/mm 3 , (GEMINI 1: 65% (20/31) compared to 90% (26/29) in the respective arms [unadjusted difference -25.1 (-45.3,-5.0)] GEMINI 2: 72% (23/32 compared to 85% (22/26) [unadjusted difference -12.7 (-33.6,8.1)] in the respective arms). (biospace.com)
  • In the pooled study population, the most common (≥5%) drug-related adverse events (AEs) were nasopharyngitis, diarrhoea and headache in both arms (dolutegravir plus lamivudine arm: 10%, 12%, and 11%, respectively, dolutegravir plus TDF/FTC: 16%, 13%, and 12%, respectively). (biospace.com)
  • 1 Drug-related AEs occurred less frequently in participants on the dolutegravir plus lamivudine arms compared with those in the dolutegravir plus TDF/FTC arms (140/716, [20%] vs 179/717 [25%] respectively). (biospace.com)
  • 1 Rates of serious AEs were comparable (64/716 [9%] vs 67/717 [9%] in the dolutegravir plus lamivudine arms versus the dolutegravir plus TDF/FTC arms). (biospace.com)
  • 1 The percentage of participants who withdrew due to AEs was 3% in each study arm (24/716 in the dolutegravir plus lamivudine arm vs 23/717 in the dolutegravir plus TDF/FTC arms). (biospace.com)
  • Kimberly Smith, M.D., Head of Global Research & Medical Strategy at ViiV Healthcare, said: "The GEMINI 1 & 2 studies have already changed the way we treat people living with HIV, with the combination of dolutegravir plus lamivudine allowing many people to reduce the number of medicines they take and manage their HIV without a third antiretroviral treatment. (biospace.com)
  • The Week 96 data further demonstrate the durable efficacy and tolerability of dolutegravir plus lamivudine. (biospace.com)
  • Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine. (tripdatabase.com)
  • Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week clinical trial results demonstrating that entecavir maintains more viral load suppression compared to lamivudine in nucleoside-naive, chronic hepatitis B e-antigen-negative (HBeAg-) patients. (presseportal.de)
  • Ninety-four percent of HBeAg-negative patients treated with entecavir for up to 96 weeks compared to 77 percent of patients treated with lamivudine achieved an undetectable viral load, defined as HBV DNA less than 300 copies per milliliter of blood (mL). (presseportal.de)
  • In addition, no evidence of entecavir resistance was identified with up to 96 weeks of entecavir treatment in patients without lamivudine resistance substitutions at baseline. (presseportal.de)
  • In the study, patients received either entecavir 0.5 mg once daily (n=325) or lamivudine 100 mg once daily (n=313) for a minimum of 52 weeks. (presseportal.de)
  • In an analysis of study results that assessed the cumulative probability of response through 96 weeks among all treatment-naive, HBeAg-negative chronic hepatitis B patients who initiated treatment with entecavir (n=325) versus lamivudine (n=313), 94 percent of patients in the entecavir treatment group achieved virologic suppression to undetectable levels, compared to 77 percent of patients given lamivudine (p (presseportal.de)
  • Additionally, the proportion of patients achieving ALT level normalization was 89 percent for patients treated with entecavir, compared to 84 percent of patients treated with lamivudine (p=0.05). (presseportal.de)
  • The safety profile of entecavir was comparable between the treatment groups, with similar incidence of serious adverse events (6 percent with entecavir, 8 percent with lamivudine) and total adverse events (76 percent with entecavir, 80 percent with lamivudine). (presseportal.de)
  • Discontinuations due to adverse events were observed in 2 percent of patients treated with entecavir versus 3 percent of patients treated with lamivudine. (presseportal.de)
  • The usual dose of lamivudine is 300mg per day. (aidsmap.com)
  • ViiV Healthcare also produces a fixed-dose combination of 300mg lamivudine with 600mg abacavir that is suitable for once-daily dosing. (aidsmap.com)
  • The dosage of lamivudine should be reduced for people who weigh less than 50 kilograms (110 pounds). (thebody.com)
  • A pharmaceutical composition in solid dosage unit form comprising a therapeutically effective amount of a new Lamivudine polymorphic form in combination with a pharmaceutically acceptable carrier is also disclosed along with a pharmaceutical composition useful for treating HIV infections in humans. (freepatentsonline.com)
  • Abacavir and lamivudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. (nih.gov)
  • Discontinue abacavir and lamivudine as soon as a hypersensitivity reaction is suspected. (nih.gov)
  • Regardless of HLA-B*5701 status, permanently discontinue abacavir and lamivudine if hypersensitivity cannot be ruled out, even when other diagnoses are possible. (nih.gov)
  • Following a hypersensitivity reaction to abacavir and lamivudine, NEVER restart abacavir and lamivudine or any other abacavir-containing product. (nih.gov)
  • Prior hypersensitivity reaction to abacavir or lamivudine. (nih.gov)
  • Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of EPZICOM (abacavir and lamivudine). (rxlist.com)
  • with previous hypersensitivity reaction to dolutegravir or lamivudine. (nih.gov)
  • The Abacavir/Lamivudine pack includes an Alert Card , to remind you and medical staff about abacavir hypersensitivity. (medicines.org.uk)
  • No convincing instances of lactic acidosis with microvesicular fat have been reported in patients with hepatitis B who typically receive lamivudine alone or in combination with adefovir or tenofovir. (nih.gov)
  • a adição Resposta-Guiada de adefovir à terapia lamivudine-baseada mantem não somente a supressão viral a longo prazo em pacientes crônicos Chineses da hepatite B com cirrose de fígado compensada, a pesquisa sugere, mas igualmente melhora a função de fígado. (news-medical.net)
  • Especificamente, os pacientes com respostas virological completas e parciais ao lamivudine, definido como níveis de HBV de 60 IU/mL ou abaixo e entre 60 IU/mL e 2000 IU/mL, de respectivamente, foram dados o adefovir além do que lamivudine em curso na semana 48. (news-medical.net)
  • Os pesquisadores indicam, contudo, que estas mudanças eram atribuíveis à terapia do lamivudine apenas nos participantes com respostas completas e parciais, mas à combinação de lamivudine e ao adefovir em pacientes inadequados da resposta. (news-medical.net)
  • Assim, os pacientes com uma resposta completa ou parcial ao lamivudine podem tirar proveito da adição de adefovir, para dizer os autores, mas, notando que os níveis do ADN de HBV não diminuíram marcada a semana 24 48 em pacientes parciais da resposta, propor o serviço adicional imediato do adefovir na semana 24. (news-medical.net)
  • The aim of this study was to assess the patterns of lamivudine (LAM)-resistant mutations and the influence on biochemical and virological responses to adefovir (ADV) add-on LAM combination therapy in patients with LAM-resistant chronic hepatitis B (CHB). (wiley.com)
  • EPZICOM contains the prescription medicines abacavir and lamivudine. (rxlist.com)
  • What are the possible side effects of abacavir and lamivudine (Epzicom)? (emedicinehealth.com)
  • Tenofovir disoproxil difumarate (tenofovir DF) is effective in chronic hepatitis B patients who are resistant to lamivudine, according to research presented at the The Liver Meeting, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). (hcplive.com)
  • Elevations in serum ALT levels occur in a proportion of patients with chronic hepatitis B treated with lamivudine. (nih.gov)
  • Lamivudine has been used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV/AIDS. (wikipedia.org)
  • Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: A meta-analysis. (tripdatabase.com)
  • The observed high frequency of lamivudine resistance may have implications for the concept of long-term virus-suppressive therapy of chronic hepatitis B by lamivudine monotherapy. (nih.gov)
  • Presents a letter to the editor about a case of reactivation of chronic hepatitis B in a patient treated long-term with lamivudine. (ebscohost.com)
  • Lamivudine for the Treatment of Chronic Hepatitis B. Dienstag, Jules L. (ebscohost.com)
  • Lamivudine treats HIV and chronic hepatitis B infections. (rxwiki.com)
  • Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). (sigmaaldrich.com)
  • Lamivudine(Epivir) generic Lamivir is a potent nucleoside analog reverse transcriptase inhibitor (nRTI), prescribed for HIV/AIDS, and hepatitis B either alone or with other medication. (medindia.net)
  • A novel four drugs combination was used, which contains two nucleoside analog reverse transcriptase inhibitors (lamivudine and tenofovir) and two protease inhibitors (darunavir and ritonavir). (ijpsonline.com)
  • Abacavir/lamivudine , sold under the brand name Kivexa among others, is a medication used to treat HIV/AIDS . (wikipedia.org)
  • Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. (wikipedia.org)
  • HIV or HBV-infected women on lamivudine are warned to discontinue breastfeeding as this puts the baby at risk for HIV transmission and medication side effects. (wikipedia.org)
  • Lamivudine may also be used for purposes not listed in this medication guide. (rexhealth.com)
  • Lamivudine is a medication used to treat HIV, originally marketed under the brand name Epivir . (aidsmap.com)
  • Abacavir and lamivudine comes with a Medication Guide and a Warning Card listing symptoms of an allergic reaction. (rexhealth.com)
  • The effectiveness of the medication depends on there being the right amount of lamivudine in your blood. (medbroadcast.com)
  • without known resistance to the medicines dolutegravir or lamivudine. (medicinenet.com)
  • Some foods and medicines can affect how lamivudine works. (umm.edu)
  • LAMIVUDINE RBX contains the medicine lamivudine which belongs to a group of medicines called antivirals. (nps.org.au)
  • Two of these medicines (abacavir and lamivudine) belong to a group called nucleoside reverse transcriptase inhibitors (NRTIs). (stjude.org)
  • Building on our innovative portfolio of medicines, Dovato is powered by dolutegravir, an antiretroviral included in multiple combination therapies and the most prescribed integrase inhibitor in the world, 2 coupled with the established profile of lamivudine. (positivelyaware.com)
  • Abacavir/Lamivudine contains abacavir (which is also an active substance in other related medicines). (medicines.org.uk)
  • If you have hepatitis B you may develop liver symptoms after you stop taking medicine that contains lamivudine. (wellspan.org)
  • The approval of the fixed dose combination of dolutegravir and lamivudine, a complete, single-tablet, two-drug regimen, marks a pivotal moment in the treatment of HIV-1. (positivelyaware.com)
  • Do not take this medicine if you have ever had an allergic reaction to any medicine that contains abacavir or lamivudine. (rexhealth.com)
  • Before initiating abacavir and lamivudine, screen for the HLA-B*5701 allele because abacavir and lamivudine tablet contains abacavir. (nih.gov)
  • HIV the drugs L-756423 plus indinavir (IDV) are compared to just IDV when taken with stavudine (d4T) and lamivudine (3TC). (bioportfolio.com)
  • The purpose of this study is to see if it is safe to give indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC) to HIV-positive patients who have nev. (bioportfolio.com)
  • [3] Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI). (wikipedia.org)
  • Dovato is a once-daily, single-tablet, two-drug regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay, 50 mg) with the nucleoside analogue reverse transcriptase inhibitor (NRTI) lamivudine (Epivir, 300 mg). (positivelyaware.com)
  • Lamivudine is an NRTI that works by interfering with the conversion of viral RNA into DNA which in turn stops the virus from multiplying. (positivelyaware.com)
  • Lamivudine belongs to a group of drugs called nucleoside reverse transcriptase inhibitors (NRTI), which block a process HIV and hepatitis B viruses need to reproduce. (rxwiki.com)
  • Lamivudine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors-NRTI. (kaiserpermanente.org)
  • Lamivudine (la miv' ue deen) is an L-enantiomer and substituted analogue of cytidine (2',3'-dideoxy-3'-3-thiacytidine: 3TC) and is active against both HIV and HBV in vitro and in vivo. (nih.gov)
  • Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. (medicinenet.com)
  • Lamivudine is also available in a single-tablet regimen, which means all the drugs for combination antiretroviral therapy in one pill. (aidsmap.com)
  • Lamivudine ( Epivir ) is able to reduce HIV viral load and increase CD4 cell counts in the majority of people when taken in combination with at least two other antiretroviral drugs. (aidsmap.com)
  • Lamivudine, sold under the brand name 3TC (Epivir in the US), is a type of antiretroviral (anti-HIV) drug called a nucleoside analogue or "nuke. (catie.ca)
  • These studies evaluate a two-drug regimen of dolutegravir and lamivudine compared with a three-drug, first-line regimen of DTG + TDF/FTC in HIV-1 infected, antiretroviral therapy (ART)-naïve adult participants with baseline HIV-1 viral loads up to 500,000 copies per milliliter. (positivelyaware.com)
  • [1] It is a fixed dose combination of abacavir and lamivudine . (wikipedia.org)
  • diabetes ( liquid lamivudine contains 3 to 4 grams of sucrose per dose). (rexhealth.com)
  • Dovato is a fixed-dose combination product containing 50 mg of dolutegravir and 300 mg of lamivudine. (medicinenet.com)
  • The maximum dose of DUTREBIS is one tablet (150 mg lamivudine/300 mg raltegravir) taken twice daily. (rxlist.com)
  • 50 mL/min, DUTREBIS should be switched to the individual components (lamivudine and raltegravir) to allow for lamivudine dose reduction. (rxlist.com)
  • Lamivudine (3TC) was found to have weak mutagenic activity in one in vitro assay, but there was no evidence of in vivo genotoxicity in rats at 35 times to 45 times the exposure observed in humans who received the standard dose. (nih.gov)
  • Cells were treated with compounds in 3-, 4-, or 8- point dose response curves with 2-fold dilutions starting at 80 µmol/L or 320 µmol/L oral lamivudine. (cdc.gov)
  • Changes in absolute CD4+ cell counts were significantly better for the low-dose and the high-dose lamivudine groups than for the zalcitabine group (median changes at 52 weeks were plus 42.5 cells/mm 3 in the low-dose lamivudine group, plus 23.33 cells/mm 3 in the high-dose lamivudine group, and − 29.58 cells/mm 3 in the zalcitabine group). (annals.org)
  • Suppression of plasma HIV RNA levels was similar for all groups (median changes at 52 weeks were − 0.48 log 10 copies/mL in the low-dose lamivudine group, − 0.51 log 10 copies/mL in the high-dose lamivudine group, and − 0.39 log 10 copies/mL in the zalcitabine group). (annals.org)
  • No significant differences in safety were seen among the three regimens, although the low-dose lamivudine regimen appeared to be better tolerated than the others. (annals.org)
  • Lamivudine is a very rare cause of clinically apparent drug induced liver injury, but is associated with flares of underlying hepatitis B during therapy or with abrupt withdrawal. (nih.gov)
  • Finally, withdrawal flares occur between 4 and 12 weeks after stopping lamivudine and can be severe, symptomatic and even lead to clinical decompensation, acute liver failure and either death or need for emergency liver transplantation. (nih.gov)
  • Patients who are infected with HIV and HCV and are on both interferon and lamivudine can experience liver damage. (wikipedia.org)
  • Lamivudine can also cause severe or life-threatening effects on your liver or pancreas. (rexhealth.com)
  • Your doctor will monitor liver tests for several months after you stop lamivudine. (webmd.com)
  • Abacavir and lamivudine can also cause serious or fatal side effects on the liver . (emedicinehealth.com)
  • Lamivudine can cause damage to the pancreas or liver, which can produce abdominal pain and nausea, discolored excrement, low fever, diminished appetite and jaundice. (sharecare.com)
  • Lamivudine can cause serious damage to the liver and a condition called lactic acidosis. (rxwiki.com)
  • Worsening of hepatitis (inflammation of the liver) when treatment with lamivudine is stopped. (rxwiki.com)
  • Liver and blood testing should continue for several months after lamivudine-HBV is stopped. (kaiserpermanente.org)
  • Rarely, lamivudine-HBV has caused severe (sometimes fatal) liver problems and a buildup of lactic acid in the blood (lactic acidosis). (kaiserpermanente.org)
  • In conclusion, the mutational pattern during selection of lamivudine resistant HBV strains differs between genotypes A and D. This may have consequences for a salvage regimen initiated for treatment of lamivudine resistant HBV. (nih.gov)
  • Dovato (dolutegravir and lamivudine) is a two-drug regimen in a single tablet that can eliminate additional toxicity and potential issues with a third drug. (science20.com)
  • The aim of the study is to establish if human immunodeficiency virus type 1 (HIV-1) infected adult subjects with current virologic suppression on a 3-drug tenofovir alafenamide (TAF) based regimen (TBR) remain suppressed upon switching to a two-drug regimen of dolutegravir (DTG) 50 milligram (mg) + lamivudine (3TC) 300 mg. (centerwatch.com)
  • Lamivudine is an analogue of cytidine. (wikipedia.org)
  • Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. (rxlist.com)
  • A better explanation of the data is that lamivudine continues to have a partial anti-viral effect even in the presence of the M184V mutation. (wikipedia.org)
  • The aim of this study was to evaluate the clinical value of oxymatrine in preventing lamivudine induced YMDD mutation using meta-analysis of data from published randomized controlled trials (RCTs) and to provide some useful information for clinical treatment and future research of YMDD mutation. (hindawi.com)
  • The Cochrane Central Register of Controlled Trials, Medline, Science Citation Index, EMBASE, China National Knowledge Infrastructure, Wanfang Database, and China Biomedical Database were searched to identify RCTs that evaluated the incidence of YMDD-motif mutation to lamivudine therapy and lamivudine plus OMTR therapies in CHB patients. (hindawi.com)
  • The purpose of this study is to evaluate the virological efficacy of maintenance therapy with atazanavir with ritonavir combined with lamivudine in treatment experienced HIV positive patients with full and stable virological suppression. (clinicaltrials.gov)
  • Virological breakthrough was preceded by 2 to 4 months by the emergence of quasispecies variants bearing amino acid substitutions at RT position 204, i.e., within the YMDD catalytic motif (rtM204V/I). Three patients had a gradual switch from a YMDD variant population at baseline to a 100% lamivudine-resistant variant population, whereas the remaining patient had a fluctuating pattern of resistance variant dynamics. (asm.org)
  • The samples were detected using a UV detector, 260 nm for lamivudine, tenofovir and darunavir and 240 nm for ritonavir. (ijpsonline.com)
  • The procedure separated analytes and its potential degradation products, in an overall analysis time of about 15 min with lamivudine, tenofovir, darunavir and ritonavir eluting at about 2.385, 4.055, 11.353 and 14.010 min, respectively. (ijpsonline.com)
  • The linear range of lamivudine, tenofovir, darunavir and ritonavir was 58.32-174.96 μg/ml, 58.32-174.96 μg/ml, 72.00-216.00 μg/ml and 112.50-337.5 μg/ml, respectively. (ijpsonline.com)
  • The combination of lamivudine and tenofovir is used along with other medications to treat HIV in adults and children. (medlineplus.gov)
  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination, including lamivudine and other antiretrovirals. (rxlist.com)
  • Side effects of lamivudine are uncommon but may include headache, nausea, fatigue diarrhea and cough. (nih.gov)
  • Abacavir and lamivudine can cause severe or fatal side effects. (wellspan.org)
  • Abacavir and lamivudine affects your immune system, which may cause certain side effects (even weeks or months after you've taken this medicine). (emedicinehealth.com)
  • Lamivudine has many possible side effects. (sharecare.com)
  • Some people taking Abacavir/Lamivudine or other combination treatments for HIV are more at risk of serious side effects. (medicines.org.uk)
  • Serious side effects can occur with lamivudine use. (rxwiki.com)
  • This is not a complete list of lamivudine side effects. (rxwiki.com)
  • You may need a blood test before you start taking abacavir and lamivudine for the first time, or if you are restarting the medicine after stopping for reasons not related to an allergic reaction. (rexhealth.com)
  • Do not use it if you had an allergic reaction to abacavir or lamivudine. (limamemorial.org)
  • if you are allergic ( hypersensitive ) to abacavir (or any other medicine containing abacavir), lamivudine or any of the other ingredients of this medicine (listed in section 6). (medicines.org.uk)
  • Lamivudine is an HIV-1 nucleoside analogue reverse transcriptase inhibitor. (rxlist.com)
  • Your doctor will prescribe lamivudine as part of your HIV treatment, along with antiretrovirals from another class of drugs. (aidsmap.com)
  • Your doctor may test you to see if you have HBV before you begin your treatment with lamivudine. (medlineplus.gov)
  • If you have new or worsening symptoms after starting treatment with lamivudine, be sure to tell your doctor. (medlineplus.gov)
  • The COLATE study has suggested that there is no benefit to continuing lamivudine treatment in patients with lamivudine resistance. (wikipedia.org)
  • with hepatitis B S-antigen (HBsAg) seropositive breast cancer who had undergone chemotherapy.Studies that compared the efficacy of treatment with lamivudine prophylaxis versus no prophylaxis in HBsAg seropositive breast cancer patients were identified through Medline, Cochrane, and Embase databases.Six studies involving 499 patients were analyzed. (tripdatabase.com)
  • In 1996, lamivudine was licensed in Europe as a treatment for HIV when used in combination with other anti-HIV drugs. (aidsmap.com)
  • Lamivudine is also approved as a treatment for HBV. (aidsmap.com)
  • How is the HBeAg seroconversion rate affected after lamivudine (3TC) treatment for hepatitis B (HBV) (Hep B)? (medscape.com)
  • Lamivudine treatment was associated with a decline in serum HBV DNA and serum transaminases in all patients. (wiley.com)
  • Lamivudine resistance develops in 53% to 76% of patients after 3 years of treatment. (asm.org)
  • We hereby report a 47-year-old treatment-naïve male, who developed severe AHB and was initially treated with lamivudine (LMV). (edu.mt)
  • Not everyone responds to treatment with Abacavir/Lamivudine in the same way. (medicines.org.uk)
  • Telbivudine achieved a proportionally higher rate of greater HBeAg responses than lamivudine, with a greater proportion of HBeAg loss and seroconversion over a 2-year treatment period. (natap.org)
  • A greater proportion of patients treated with telbivudine therefore qualified for treatment discontinuation due to HBeAg seroconversion, compared with lamivudine. (natap.org)
  • The post-treatment durability of HBeAg seroconversion with telbivudine was more than 85% by Kaplan Meier estimate after 52 weeks of off-treatment follow-up, and was comparable to lamivudine. (natap.org)
  • These results suggest that most patients will have sustained off-treatment seroconversion after at least 6 months of treatment consolidation following HBeAg seroconversion with either telbivudine or lamivudine. (natap.org)
  • Two large phase III trials comparing treatment with telbivudine and lamivudine over a 2-year period were conducted in adult patients with CHB. (natap.org)
  • Historically, trials reporting durability of HBeAg seroconversion with lamivudine treatment have reported limited durability (relapse rate 56%) of HBeAg seroconversion.8 These data may not be relevant to modern clinical practice, because standard methodology was not used, and in particular, no consolidation treatment was offered to patients. (natap.org)
  • The aim of this analysis was to assess off-treatment durability of response in HBeAg-positive patients followed for up to 52 weeks after discontinuation of telbivudine or lamivudine therapy in the combined populations of studies 007 and 015. (natap.org)
  • HIV counseling and testing should be offered to all patients both before and during treatment with lamivudine-HBV. (kaiserpermanente.org)
  • A total of 1211 HBeAg-positive patients were enrolled into these two trials: 458 and 463 HBeAg-positive patients were treated with telbivudine and lamivudine, respectively, in the GLOBE study, and 147 and 143 telbivudine- and lamivudine-treated HBeAg-positive patients, respectively, were studied in the 015 trial. (natap.org)
  • Lamivudine is phosphorylated intracellularly to the triphosphate which competes with the naturally occurring cytidine triphosphate for incorporation into the growing HIV or HBV DNA chain by the viral polymerase, thereby inhibiting polymerase (or reverse transcriptase) activity and causing chain termination. (nih.gov)
  • The current data suggest that lamivudine does not directly inhibit EBOV RNA polymerase or replication of the virus. (cdc.gov)